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Abstract
Positron Emission Tomography (PET) is an imaging technique that allows for in
vivo quantification of biochemical and physiological processes in the brain. Examples
of targets in the brain that can be imaged using PET are dopamine receptors
and the translocator protein 18kDa (TSPO). Following intravenous injection of a
radio-labeled ligand and the ensuing PET examination of a subject, kinetic models
are often used to estimate parameters of interest. Example of such parameters are
binding potential or distribution volume, which are estimates of the availability of
receptors in a specific region or volume-element of the brain. These parameters can
then be inserted into statistical models to infer e.g. differences in target availability
between patients and controls or relationships to behavioral traits. In order to detect
effects of interest, it is important that the estimation of these parameters is precise,
reliable and valid. The aim of this thesis was to evaluate different methods for
estimating such parameters, and apply them on clinical data.
The thesis consists of two different themes. The focus of theme I was the quantification
of dopamine receptor in striatum and the cortex, and their relationship to normal
and dysfunctional social behavior.
Study I and Study II examined the relationship between dopamine D1 receptor
availability and self-rated pro and anti-social behavior in healthy subjects. Study
I found a positive correlation between striatal D1 receptor availability and Social
Desirability, and a negative correlation to Trait Aggression. Study II did however
fail to replicate these results.
In Study III, dopamine D2 receptor availability in limbic and cortical regions in
patients with social anxiety disorder and healthy controls were compared. Exploratory
analyses suggested that patients had higher D2 receptor availability in the lateral
and orbitofrontal cortex, although the results warrant replication in a larger sample.
The focus of theme II was the quantification of TSPO in patients with psychosis and
healthy subjects. The level of TSPO in the brain has been hypothesized to function
as an index of microglial cell activity, which in turn is believed to be a proxy for
immune activation in the central nervous system.
In Study IV, [11C]PBR28 binding in the whole grey-matter in patients with
first-episode psychosis and healthy controls were compared. Contrary to the
hypothesis of elevated microglia activity, patients were found to have lower TSPO
levels.
Study V evaluated the test-retest reliability and convergent validity of different
methods to measure TSPO levels using [11C]PBR28. Distribution volume ratios and
standardized uptakes value ratios, derived using pseudo-reference regions, showed
both poor reliability and convergent validity.
Study VI carried out a meta-analysis of TSPO in patients with schizophrenia and
psychotic disorders compared to healthy controls. Again, contrary to the hypothesis
of higher microglia activity, strong evidence was found in favor of patients having
lower TSPO levels in both cortical and subcortical regions.
In Study VII, the test-retest reliability and convergent validity of different methods
to estimate TSPO levels using (R)-[11C]PK11195 were evaluated. Outcomes derived
using pseudo-reference region approaches were unreliable and showed no convergent
validity to outcomes derived using arterial input function.
Finally, Study VIII evaluated the reliability and accuracy of a new modeling
method, applied to [11C]PBR28 data, in order to estimate specific binding without
requiring a reference region. Simulations, a pharmacological challenge and test-retest
analysis showed that non-displaceable distribution volume, and ensuing specific
distribution volume values, derived using this method were accurate, precise and
reliable.
Taken together, the results of the studies illustrate the importance of evaluating
quantification methods prior to applying them on clinical data. The thesis also shows
how robust kinetic and statistical modeling, and the use of direct replications or
multi-center collaborations, can yield more trustworthy and reliable findings in PET.
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11C carbon-11
18F flour-18
2TCM two-tissue compartment model
ABSS arterial blood sampling system
AbsVar absolute variability (or test-retest variability)
AIF arterial input function
ANCOVA analysis of covariance
AUC area under the curve
BF Bayes factor
BPND binding potential non-displaceable
CER cerebellum
D1-R dopamine D1 receptor
D2-R dopamine D2 receptor
D3-R dopamine D3 receptor
DLPFC dorsolateral prefrontal cortex
DVR distribution volume ratio
FEP first episode psychosis
FWHM full width at half maximum
GM whole-greymatter
HAB high affinity binders
HR ECAT Exact High Resolution system
HRRT ECAT Exact High Resolution Research Tomograph system
ICC intra-class correlation coefficient
IPD individual participant data
KI Karolinska Institutet
MAB mixed affinity binders
MD minimum detectable difference
MRI magnetic resonance imaging
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OFC orbitofrontal cortex
PET positron emission tomography
ROI region of interest
SAD social anxiety disorder
SEM standard error of measurement
SNR signal-to-noise ratio
SPM statistical parametric mapping
SRTM simplified reference tissue model
SSP Swedish universities Scales of Personality
SUV standardized uptake values
SUVR standardized uptake value ratio
SVCA supervised cluster analysis
TAC time-activity curve
TSPO translocator protein 18kDa
Vb fractional blood volume
VND non-displaceable distribution volume
VS specific distribution volume
VT total distribution volume
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Chapter 1
Introduction
Essentially, all models are wrong, but some are useful.
– George E.P. Box
1.1 Dopamine receptors
The human brain contains around 86 billion neurons, approximately making up
50% of the total cell count (1 ). After depolarization, some neurons can release
transmitters from the terminal part of the axon into the synaptic cleft. These
neurotransmitters bind to receptors that are located on the post-synaptic neuron.
When the receptors are stimulated they evoke excitatory or inhibitory responses,
either through direct (ionotropic receptors) or indirect (G-protein coupled receptor)
gating of ion channels (2 ).
The monoamine neurotransmitter dopamine mainly binds to two families of receptors:
dopamine D1-Receptors (D1-R) and dopamine D2-Receptors (D2-R). D1-R are
coupled to a stimulatory G-protein structure that activates adenylyl cyclase enzyme,
leading to a cascade of second messenger functions within the post-synaptic neuron.
D2-R are coupled to a G-protein structure that inhibits the activation of adenylyl
cyclase formation. Activation of D1-R and D2-R lead to changes in the membrane
potential and the biochemical state of the post-synaptic neuron (3 ), propagating
the signal further. There is however still much to be discovered about the exact
mechanisms and effects of dopamine transmission.
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Dopamine is produced inside cell bodies in the substantia nigra and the ventral
tegmental area. Three major pathways in the primate brain arises from the axon
connections of these cells: 1. the nigrostriatal pathway, projecting from substantia
nigra to the dorsal striatum, 2. the mesolimbic pathway, projecting from the ventral
tegmental area to the ventral (limbic) striatum and other limbic structures, and 3.
the mesocortical pathway, connecting from the ventral tegmental area to cortical
regions (4 ). Dopamine and dopamine receptors are involved in a wide array of
behavioral phenotypes, such as movement (5 ), attention (6 ), motivation and learning
(7 ), addiction (8 ), and many different psychiatric and neurological disorders (9–11 ).
1.2 Glial cells
The human brain contains a large number of glial cells, of which microglia and
astrocytes are common subtypes (12 ). One important role of microglial cells is to
respond to infections (13 ). As resident macrophages they exterminate cellular debris
and are involved in the presentation of antigens and signaling of cytokines (14 ).
They play an integral role in attacking invading cells, removing damaged cells and
fragments, and by promoting neural tissue repair (15 ). Microglia activity is thought
to be upregulated when there is an infection or inflammation in the central nervous
system (16 ). However, healthy subjects, without any acute immune-activation, can
also express microglia throughout the entire brain (17 ). Astrocytes function as
support cells in the brain and constitute around 20% of glial cell population of the
human brain (18 ). Among other things, they provide nutrients to neurons and are
involved in repair of damaged tissue (19 ). Importantly, activation of glial cells could
have both beneficial and detrimental effects on the central nervous system pathology
(20,21 ).
1.3 Overview of positron emission tomography
Positron Emission Tomography (PET) is a functional imaging technique that allows
for in vivo examination of neurochemical targets and physiological processes, such
as receptors and transporters, neurotransmitter release, blood flow and glucose
metabolism. PET imaging relies on the decay of isotopes with short half-life, such
as Carbon-11 (11C) or Flour-18 (18F). By replacing an atom on a medical compound
with a suitable isotope, a radioligand (or radiotracer) is constructed and can be
13
used as an imaging marker. Examples of such radioligands are [11C]SCH23990
which has high affinity for D1-R, [11C]FLB457 which has high affinity for D2-R,
and [11C]PBR28 which binds to the Translocator Protein 18kDA (TSPO), found in
microglia, astrocytes and white blood cells (22–24 ).
1.3.1 The PET examination
During a PET examination, the radioligand is normally administered to the subject
by injection, and delivered to the brain via the blood stream. When the isotope
attached to the ligand decays it releases a positron that travels approximately
1mm, before interacting with an electron. The ensuing collision annihilates both
particles and two resulting photons are emitted in a random direction separated by
approximately 180± 0.25◦ (25 ). The photons travel through tissue, cerebral spinal
fluid, skull and air before being detected by the PET system and registered as a
coincidence count. During a single PET measurement, multiple coincidences are
registered and form the measured projections from the 3D object positioned in the
system. This is the raw data from which the image can be reconstructed.
The goal of PET reconstruction is to recreate to 3D object that gave rise to the
measured projections. Simplified, a frame of a PET examination can be thought of
as a set of 2D images (slices) that when stacked on top of each other forms the full
3D image. There are different ways to reconstruct these slices. For the Karolinska
Institutet (KI) PET examinations included in this thesis, two procedures have been
used: 1) filtered back projection (used for the ECAT Exact High Resolution system
(HR), Siemens Molecular Imaging, Knoxville, TN, USA) and 2) ordered subset
expectation maximization (used for the ECAT Exact High Resolution Research
Tomograph (HRRT) system, Siemens Molecular Imaging, Knoxville, TN, USA).
A full PET measurement often takes between 50 to 120 min, most often depending
on the isotope that is being used. During this time the brain uptake and washout of
radioligand can be measured by obtaining the radioactivity concentration in short
time intervals called “time frames”. The length of each frame is determined by
the preferred temporal resolution (often set to be high in the initial phase of the
examination and low in the end) and the half-life of the isotope.
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Figure 1.1: Schematic of a coincidence count in the PET system. When the isotope
on the ligand complex decays, a positron (e+) is emitted. The positron travels
approximately 1mm before colliding with an electron (e−) and both particles are
annihilated, resulting in a photon pair. If both photons hit the detectors within
a specified time-window, a coincidence is registered and a line-of-response can be
established.
1.3.2 Compartmental models
In order to obtain the regional estimates of radioligand concentration, regions of
interests (ROIs) are usually delineated on a magnetic resonance imaging (MRI) T1
weighted image. The T1 image is then co-registered to the PET image and regional
concentration of radioactivity (measured in e.g. MBq/cc) of frames can be extracted.
This results in ROI time-activity curves (TACs).
In order to quantify the metabolic or biochemical parameter of interest in the
ROI, such as the density of a receptor, a kinetic model is used. The task of the
kinetic model is to describe the TAC while differentiating the concentration of
radioligand into various compartments. Depending on which ligand that is being
used, different number of compartments and different descriptions of the transfer
rates of concentration between compartments are necessary (26 ). A common and
widely applicable kinetic model for describing the TAC and the concentration in
15
Figure 1.2: Upper panel: The two-tissue compartment model. Lower panel: The
simplified reference tissue model. The boxes represent radioligand concentration in
plasma (CP ), the non-displaceable compartment (CND), the specific compartment
(CS), the target region (CT ) and the reference region (CR).
tissue is the two-tissue compartment model (2TCM; Figure 1A, (27 )).
The rate constants (K1, k2, k3, k4 in Figure 1.2) describe the rate of transfer of
radioligand to and from the different compartments. Using these rate constants, a
set of differential equations can be set up to mathematically describe the exchange
of radioligand between compartments:
dCND
dt
= K1Cp(t)− k2CND(t)− k3CND(t) + k4CS(t) (1.1)
dCS
dt
= k3CND(t)− k4CS(t) (1.2)
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where CS is the radioligand concentration in the specific compartment (specifically
bound to the target of interest) and CND is the radioligand concentration in the
non-displaceable compartment (not specifically bound the the target of interest).
In practice, however, the PET system cannot differentiate between CS and CND.
Instead the sum of the two becomes the total concentration of radioligand in a ROI:
CT (t) = CND(t) + CS(t) (1.3)
The solution of equation 1.1 and equation 1.2 leads to a formula for describing the
total concentration (CT ) of radioligand in a ROI:
CT (t) = Cp(t)⊗ (ae−ct + be−dt)
with a = r(k3 + k4 − c)
b = r(d− k3 − k4)
c = (s− e)/2
d = (s+ e)/2
e =
√
s2 − q
q = 4k2k4
r = K1/e
s = k2 + k3 + k4,
(1.4)
where Cp(t) represents the concentration of unchanged radioligand in arterial plasma
and is obtained by sampling arterial blood during the PET measurement. As such,
Cp(t) is also known as the arterial input function (AIF) and the exponential to the
right of the convolution in equation 1.4 is known as the impulse response function.
The ROI will also contain a substantial amount of intravascular radioactivity, called
whole-blood concentration (Ca) in the beginning of the PET measurement that is not
accounted for by the model described in equation 1.4. The fractional blood volume
(Vb) can therefore be added to the model:
Cmeasured(t) = (1− Vb)CT (t) + VbCa(t) (1.5)
where Cmeasured is the measured radioactivity obtained by the PET system during
an examination. The rate constants are obtained by fitting equation 1.4 to a TAC,
which has been corrected for Vb. Once obtained, the rate constant can be used to
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derive parameters of interest, such as the total distribution volume (VT). For the
2TCM, VT is calculated as:
VT =
K1
k2
(
1 + k3
k4
)
(1.6)
VT is defined as the total concentration of radioligand in the ROI over the total
concentration in plasma. A VT of e.g. 2 means that 2ml of plasma is needed to
account for the radioactivity in 1ml of tissue. As such VT is an index of radioligand
binding to target. This outcome can be used in inferential statistical designs, e.g. in
order to quantify differences in target availability between patient and control groups.
1.3.3 Simplified compartmental models
Many different expansions and simplifications have been derived from the 2TCM.
Consider for example a region of the brain with negligible specific binding of
radioligand. If such a region exists the input function can be described using
only rate constants and the concentration of radioligand in this region, a.k.a the
non-displaceable compartment or “reference region” (Figure 1.2). This allows for
quantification of non-displaceable binding potential (BPND) without the need for
arterial blood sampling to establish an AIF (27 ). BPND is a measure of specific
radioligand binding. It is defined as the concentration in the specific compartment
over the concentration in the non-displaceable compartment. BPND is proportional
to availability of the target:
BPND =
Bavail
Kd
fND (1.7)
where Bavail is the density of the available binding sites, 1/Kd is the affinity of
the radioligand and fND is the fraction of free radioligand in the non-displaceable
compartment. Assuming that the affinity and free fraction of radioligand is similar
between the subjects or the groups that are being compared, BPND can be thought
of as an index of the density of the available target sites.
If a radioligand has very fast kinetics between the non-displaceable and the specific
compartments, the model can be simplified by collapsing these two compartments
into one. One such model is the Simplified Reference Tissue Model (SRTM) (28 ):
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CT (t) = R1CR +
{
k2 − R1k21 +BPND
}
CR(t)⊗ e−
k2t
1+BPND (1.8)
The number of parameters have now been reduced, leaving only R1 (the ratio of K1
over K ′1), k2 and BPND to be fitted. The SRTM often has the advantage of showing
less variability (higher reliability), although this can come with a cost of increased
bias (lower accuracy) of the outcome measure BPND (29 ).
1.3.4 Linear models
Fitting the models described in equation 1.4 and 1.8 requires non-linear optimization.
This can be a time-consuming process if there is a substantial amount of TACs that
have to be modeled. An example of this is when a BPND value has to be derived
for each separate volume element (voxel) in the brain. For this reason, full-tissue
compartment models and simplified tissue compartmental models have been linearized,
allowing for substantially faster optimization. There are also “compartmental free”
linear models, that make less assumptions about the radioligand kinetics in different
tissue types in the brain. Examples of linear models are Multilinear Analysis 1 and
2 (30 ), Multilinear Reference Tissue Model (31 ) and the Logan Plot (32 ).
1.3.5 All models are wrong
All kinetic models described above are only approximations of real biological processes.
Such models might be useful in order to estimate a biological entity of interest but
are not guaranteed to yield precise or even meaningful outcomes. The fact that
one model has worked well to describe the availability of target for one radioligand
under certain conditions, does not mean that the same model will be useful for other
radioligands. All outcomes will also have more or less uncertainty attached to them,
either due to biological variability, measurement error or because of faulty model
assumptions. Hence, the e.g. point-estimated VT or BPND value of a subject does
not represent the absolute “true” binding, availability or density of target, but rather
only a likely value among a set of many likely values. This inherent uncertainty
around PET outcomes measures are rarely acknowledged in literature (or in this
thesis), although there exist methods to account for it (33 ).
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1.4 Imaging dopamine receptors in social behavior
1.4.1 Interpersonal personality traits
In personality literature, social behavior is commonly classified into two orthogonal
dimensions, 1. agency (or dominance) and 2. affiliation (or agreeableness). This
means that a person can display social behavior that are combinations of these two
traits, such a high agency and low agreeableness (i.e. being aggressive and hostile)
or high agency and high affiliation (i.e. being extroverted and gregarious) (34 ). The
interpersonal traits described by this model are thought to be both descriptive and
predictive of psychiatric disorders (35,36 ).
1.4.2 D2-R and Social Desirability
Previous PET studies have investigated the relationship between the pro-social
personality traits Social Desirability and D2-R availability in striatal (37–41 )
and extrastriatal regions (40 ). In the two-dimensional theory mentioned above,
measurements of Social Desirability are positioned as a combination of low dominance
and high agreeableness (40 ). The trait reflects how a person acts in order to gain
approval or acceptance by others (42 ). Most previous studies found a negative
relationship between Social Desirability and D2-R binding in the striatum (37–40 ),
with one study reporting a null-finding (41 ). Importantly, these previous studies
found significant associations in different parts of the striatum. When using the
whole-striatum as ROI for all studies, and including unpublished personality data
from a samples of twins examined with [11C]raclopride at the KI PET center, a
random effects meta-analysis suggest that there is a modest negative correlation
between D2-R availability and Social Desirability (Figure 1.3). One caveat to this
analysis is that the funnel-plot (not shown) reveals potential publication bias. Hence,
if the true effect is not null, it is likely to be smaller than presented in Figure 1.3.
1.4.3 D1-R, Social Desirability and aggression
The relationship between pro- and anti-social personality traits and the D1-R has
not been as thoroughly investigated as for the D2-R. One study in mice suggest that
D1-R expression is associated with anti-social behavior and may have an opposite
role to D2-R in mediating aggression (43 ). In humans, measurements of Social
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Figure 1.3: Meta-analysis of correlations (with 95% CIs) between self-rated reports
of Social Desirability and D2-R availability in the whole-striatum. Social Desirability
was measured by self-reported personality questionnaires and striatal D2-R availability
was measured using [11C]raclopride or [123I]iodo-benzoaminde.
Desirability have consistently been found to have high but negative loadings with
aggression scales in exploratory component analyses (44 ). This suggests that the
Social Desirability and aggression scales tap a common underlying pro-social (or
anti-social) dimension, although in opposite direction of each other. In the mice study
(43 ), increased levels of D1-R were related to higher levels of pro-social behavior,
while the opposite pattern was found for aggression. If this relationship was also
to be found in humans, it would suggest opposite regulatory mechanisms for the
D1-R and D2-R systems in mediating pro- and antisocial behavior. This in turn
could have implications for diagnosing and treating psychiatric conditions associated
with dysfunctional social behavior, such as antisocial personality disorder or social
anxiety.
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1.4.4 D2-R and social anxiety disorder
Social anxiety disorder (SAD), also known as social phobia, is one of the most
common anxiety disorders with a 12 months prevalence of around 18% (45 ). SAD is
characterized by fear and avoidance of social interaction and scrutiny by other people
(46,47 ). The dopamine system is involved in both fear processing (48 ) and avoidance
learning (49 ). Together with the tentative role for D2-R in Social Desirability, these
results suggest that an altered D2-R system may be involved in the pathophysiology
of SAD.
Single-photon emission tomography and PET studies on the D2-R in SAD have
however produced conflicting results. There have been reports of both lower levels
(50 ) and no change (51 ) in D2-R availability in patients as compared to healthy
controls. Importantly, these studies have focused on the striatum, while blood flow
and activation studies have mainly shown that extrastriatal regions are involved
in the pathophysiology of SAD. Specifically, many functional MRI studies have
reported altered activation in voxels within the amygdala, anterior cingulate, insula,
orbitofrontal (OFC) and medial frontal cortex in the disorder (52,53 ). Prior to this
thesis, there have been no studies investigating extrastriatal D2-R availability in
SAD patients compared to healthy controls.
1.5 Imaging TSPO in psychosis
1.5.1 Schizophrenia
Schizophrenia is a heterogeneous neuropsychiatric disorder characterized by delusions,
hallucinations, disorganized speech, grossly disorganized or catatonic behavior or
negative symptoms, such as lack of motivation or poverty of speech. In order for
people to be diagnosed with schizophrenia, they should display at least two of these
symptoms for a minimum period of six month (or less if successfully treated) (54 ).
The lifetime prevalence of schizophrenia is about 0.5% (55 ) and the disorder is
associated with significant impairment of social and occupational life.
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1.5.2 Immune hypothesis of schizophrenia
An altered or aberrant immune system has been hypothesized as one of underlying
reasons for the genesis or progression of schizophrenia. This hypothesis gains support
many different fields of research: 1) studies have found that genetic loci associated
with schizophrenia were expressed in tissues critical for immune function (56 ), 2)
epidemiological studies have shown that pre- and postnatal infection is associated
with later onset of the disorder (57,58 ), 3) pharmacological studies have shown that
Cox-inhibitors have positive add-on effects to anti-psychotics (59 ) and 4) studies
have shown aberrant expression of immune markers in patients, such as up-regulated
cytokine levels in plasma in chronic (60 ) and in drug-naive (61 ) patients. In the brain,
cytokines are mainly released by microglia and astrocytes. Due to these increased
levels of cytokines, it has been hypothesized that microglia and astrocytes will also
show up-regulated numbers or activity in patients with schizophrenia (62,63 ).
Initial post-mortem studies have reported increases in microglial cells, and in
some cases also astrocytes, in brains of schizophrenic patients (64–67 ). However,
later large-scale meta-analyses on post-mortem brains have revealed mixed results
regarding the expression of these cells in psychotic disorders, showing substantial
heterogeneity in the direction of patient-control differences (68,69 ). Changes in cell
expression at the time of death, methodological differences in labeling and counting
cells, as well as the use of different immunohistochemical markers could in part
explain some of the variation in results. Common limitations in these in vitro studies
were that control subjects and patients often were old at the time of death, and the
cause of death was often suicide (70 ).
1.5.3 Translocator protein 18kDa
TSPO is located on the outer mitochondrial membrane of many different cell types
in the mammalian body, such as microglia and astrocyte brain cells. It has been
hypothesized that when there is an on-going inflammation in the central nervous
system, microglia become activated and the levels of brain TSPO is increased (71,72 ).
If true, this would make the TSPO a suitable in-vivo biomarker for neuroinflammation
or brain immune-activation. It is however important to note that upregulated levels
of TSPO might reflect pathological processes other than immune activation, such as
discrete neurotoxic damages or abnormalities in cell metabolism, energy production
and oxidative stress (73 ). In fact, even healthy individuals, without an activated
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immune system, might also show high levels of TSPO in e.g. dormant microglial cells
(17 ).
1.5.4 First generation TSPO radioligands
The (R)-[11C]PK11195 PET radioligand has been used since the mid 90s with the
aim of imaging TSPO expression in the human body and brain. (R)-[11C]PK11195
has been applied in a range of studies aiming to investigate neuroinflammation in a
wide set of disorders, such as Alzheimer’s disease (74 ), multiple sclerosis (75 ), major
depression (76 ) and schizophrenia (77–81 ).
1.5.5 Second generation TSPO radioligands
Concerns regarding the low signal to noise ratio (82–84 ), and poor reliability
(85 ) of (R)-[11C]PK11195, sparked the development of a set of second-generation
TSPO radioligands. These included tracers such as [11C]PBR28 and [11C]DPA713,
which show greatly improved specific binding (86 ) as well as higher reliability (87 ),
compared to (R)-[11C]PK11195. However, the binding affinity of all second-generation
radioligand are affected by a genetic polymorphism, the rs6971-allele, resulting in
three binding-types: high affinity binders (HABs), mixed affinity binders (MABs)
and low affinity binders (LABs) (88,89 ). E.g. HABs has double the affinity for
[11C]PBR28 radioligand binding to TSPO, which result in higher binding estimates
compared to MABs, even if the true density of TSPO is the same. The distribution
of HABs, MABs and LABs in the Caucasian population is approximately 49%, 42%
and 9% respectively, while the presence of the low affinity allele is generally lower in
the Afro-American, Han Chinese or Japanese populations (90 ). These differences
in affinity makes it important to screen and control for the TSPO genotype when
performing PET studies using the second-generation TSPO radioligands.
1.5.6 Arterial input function or pseudo-reference region
approaches
TSPO is expressed throughout the entire brain, and for this reason no brain region can
serve as reference in a kinetic model. Instead, arterial samples of metabolite-corrected
plasma have to be obtained and used as AIF in a kinetic model. VT, which is one of
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the the most widely applied outcome in PET, is often derived from a kinetic model
using such an input function. Obtaining an AIF is difficult as it can be uncomfortable
for the research subjects, require specialized research equipment and skills, laborious
for the research personnel, and prone to measurement error. For these reasons, there
have been many suggestions of alternative methods to quantify the binding of first
and second generation TSPO radioligands in the brain, that do not make use of an
AIF. One of the most common and simple approaches is to use standardized uptake
values (SUVs). A SUV is calculated by dividing the radioactivity concentration in
the TAC (cTAC) with the injected radioactivity (cinj) and the body weight (BW) of
the subject for all time points:
SUV (t) = cTAC(t)
cinj/BW
(1.9)
The average, or the area under the curve (AUC), of the SUV over a time interval is
then often taken as the final outcome measure.
Another approach to quantify radioligand binding in the abscence of an AIF or
reference region is to use a “pseudo-reference region” (91,92 ). A pseudo-reference
region is simply a region that contains specific binding, but the binding is assumed
to be either low, or show negligible differences between the subjects or the groups
that are being compared.
One way to use such a pseudo-reference region is to divide the SUV in a target ROI
with the SUV in the pseudo-reference region. For [11C]PBR28, this approach has
been suggested to produce an outcome, standardized uptake value ratios (SUVRs),
with higher sensitivity to detect clinical effects (91,92 ). Another way is to use
the pesudo-reference region in a kinetic model, such as the SRTM, and derive
“pseudo-BPND” values. This has been suggested to be suitable method for estimating
e.g. (R)-[11C]PK11195 binding (79,81 ).
Even if VT values have been obtained, the use of this approach (e.g. dividing a VT
value in a target ROI with that in a pseudo-reference region) has been suggested
to be a suitable variance-reducing strategy allowing for more precise comparison of
subjects or groups (93 ). However, such suggestions have not been without criticism
(94 ). One important question is how much relevant biological signal remains in the
target ROI after the division with a pseudo-reference region.
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1.5.7 TSPO imaging in psychosis
The first PET studies to examine TSPO expression in schizophrenia were published
over a decade ago and used the first-generation TSPO radioligand (R)-[11C]PK11195.
In a sample of 10 patients with recent onset schizophrenia and 10 control subjects
(77 ), the authors reported higher levels of whole grey-matter TSPO binding in
recent-onset schizophrenia (p=0.048), using specific distribution volume (VS) as
outcome measure. This was followed by a study with 7 patients with psychotic
disorder and 8 healthy controls where patient (R)-[11C]PK11195 BPND (k3/k4) was
shown to be higher in the hippocampus after normalizing to whole grey-matter BPND
(pcorrected=0.04) (78 ). Later studies, which have not made used of AIFs, have reported
mixed findings, with patients showing both higher and no-differences in pseudo-BPND
values (79–81 ). Since no reference region exists for TSPO, these pseudo-BPND values
were derived using SRTM with TACs from the supervised-cluster analysis (SVCA)
(95,96 ), or the cerebellum, as reference input.
Table 1.1 shows all published (R)-[11C]PK11195 studies in schizophrenia or psychosis
using the whole of grey-matter as ROI. In these studies, different outcome measures
have been used, and it’s not clear whether or not the effect sizes can be entered into
the same meta-analysis model: First, the reliability and precision of the outcomes
measures have not yet been established. Second, the outcome measures likely show
different sensitivity and precision for patient-control differences.
Table 1.1: (R)-[11C]PK11195 patient-control comparisons of schizophrenia or
psychotic disorder using the whole grey-matter as ROI. Pseudo-BPND values were
derived using either a cerebellum (CER) TAC or a TAC from the supervised cluster
analysis (SVCA) as reference input.
Study and
subsamplea
N
controls/patientsb Used AIF Outcome
Patient
Mean (SD)
Control
Mean (SD) reported p Hedges’ g
van Berckel et al., 2008
10/10 yes VS (BPP ) 1.89 (0.32) 1.62 (0.3) <0.05 0.83
Doorduin et al., 2009
8/7 yes BPND 1.99 (0.64) 1.54 (0.41) 0.122 0.80
Holmes et al., 2016
Medicated 16/8 no pseudo–BPND CER 0.16 (0.11) 0.09 (0.05) 0.032 0.95
Drug-free 16/8 no pseudo–BPND CER 0.09 (0.07) 0.09 (0.05) 0.981 0.08
van der Doef et al., 2016
17/19 no pseudo–BPND SVCA 0.17 (0.09) 0.14 (0.09) 0.3 0.33
di Biase et al., 2017
Chronic 15/18 no pseudo–BPND CER 0.9 (0.04) 0.9 (0.04) NA 0.12
Rescent onset 12/15 no pseudo–BPND CER 0.87 (0.05) 0.89 (0.04) NA -0.29
a di Biase et al., 2017 (81) did not examine whole grey-matter. Instead reported ROI pseudo-BPND values have been averaged.
b The same healthy control sample was used for both patient samples in Holmes et al., 2016 (79)
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To date, five studies have been published on differences between psychosis patients
and healthy controls using second-generation TSPO radioligands, excluding Study
IV from this thesis (93,97–100 ). Four of these studies did not find support for the
hypothesis of higher levels of TSPO (estimated using VT) in the brain of patients
compared to control subjects (93,97–99 ). One study (100 ) did however find a
significant interaction effect of age and patient-control groups on VT (with older
patients showing higher VT values in grey matter). This finding emerged after entering
all subjects as random effects into a linear mixed effects model and covarying for
TSPO genotype, age, cohort by age, cohort by genotype and age by genotype.
1.6 Statistical inference of PET outcome measures
Two schools of inference have been applied in this thesis: frequentist and Bayesian
statistics. In frequentist inference the aim is to calculate the probability of
obtaining the observed, or more extreme data, given that the null-hypothesis is
true. Broadly speaking, frequentist statistics can be divided into two groups, 1)
Fisherian inference (101,102 ) and Neyman-Pearson Null-Hypothesis-Testing (103 ).
In Fisherian statistics, the p-value is meant to capture surprise. I.e. assuming that
the null-hypothesis is true, the researchers obtain an estimate on how surprised they
should be by the observed data. If the data is deemed to be very surprising (i.e. the
p-value is very low), this is taken as indirect evidence against the null-hypothesis.
In a Neyman-Pearson framework, the p-value allows researchers to perform
error-control, conditioned on the null-hypothesis being true. I.e. if the p-value falls
below a pre-defined threshold (such as 0.05), then the researcher knows that if they
act like the null is false they will not be wrong more than 5% of the time.
In Bayesian inference, statistical parameters, such as regression coefficients, are
represented by probability distributions. A probability distribution reflects both the
researcher’s belief in, and the uncertainty around, different values for that parameter.
The observed data is then used to update these distributions, to arrive at posterior
distributions. A posterior distribution represents the researcher’s updated belief
about the probability, and uncertainty, of different values of the parameter (104,105 ).
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1.6.1 All models are wrong, again
Contrary to semi-popular belief, there exist no statistical model or inference that is
inherently “objective”. I.e. there are no statistical models were data only speaks for
itself and results are independent of the choices and beliefs of the researchers. All
models, frequentist and Bayesian, involves making a wide array of subjective choices
and assumptions, such as the use of likelihood function, regularizing coefficient,
hierarchical or non-hierarchical treatment of data, alpha thresholds, null-intervals
of interest, division of training and testing data sets, fit-metrics and procedures for
model-averaging, and prior distributions. Using a pre-packaged statistical model,
such as an ANOVA, might give the illusion of producing objective results, but
applying it “off the shelf” merely entails that somebody else made subjective choices,
often hidden in the model.
1.6.2 Pre-registration, reproducibility and replication
There is a growing awareness in neuroscience that pre-registration, reproducibility
and direct replication of studies are important for improving the trustworthiness
and robustness of findings (106–108 ). Pre-registration is when researchers publicly
pre-register the study design, data and/or statistical analysis procedures. I.e. they
declare what they are going to do before they do it. Ideally, pre-registration should
be done prior to collecting any data. This helps in combating three major issues in
the scientific literature: 1) publication bias (also known as the “file drawer problem”),
2) creating hypotheses and presenting results as confirmatory only after the results
are known (also known as “Hypothesizing After the Results are Known” (109 )),
and 3) analytical flexibility, such as switching outcomes and covariates or dropping
outliers in order to obtain positive findings (also known as “p-hacking”).
If a study or analysis is reproducible, it means that it possible for the results to
be reproduced and recreated by an independent researcher. This includes practices
of open data sharing and public sharing of analysis code and study procedures
(108 ), which in turn makes post-publication peer review by the scientific community
possible.
A direct replication is when an identical (or very similar) study design, data and/or
statistical analysis procedures are applied on a new and independent data set, with
the aim of replicating the results of a previous published study (110 ). This helps in
assessing the robustness of published findings and combating p-hacking as well as
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other questionable research practices (106,111,112 ). In PET literature there is to
date little practice in pre-registering the study or statistical analysis protocol, make
analyses reproducible or initialize and publish direct replication studies.
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Aims
The thesis consists of two themes:
I. Examine the relationship between dopamine receptors and normal as well as
dysfunctional social behavior (Study I-III).
II. Apply and evaluate methods for examining brain levels of TSPO in psychosis
(Study IV-VIII).
The first aim of theme I was to examine the relationship between D1-R and pro and
anti-social behavior, measured using scales from self-rated personality questionnaires.
The second aim was to examine differences in extrastriatal D2-R levels between
patients with SAD and healthy control subjects.
The aim of theme II was to examine brain TSPO levels, hypothesized to be an
index of glial cell activity, in patients with psychosis or schizophrenia as compared
to healthy control subjects. Since there exist many different approaches to quantify
TSPO binding, a further aim was to examine the reliability, accuracy and validity of
such approaches. This was done in order to both aid the interpretation of already
published clinical findings, and to evaluate which quantification method would be
suitable to apply in future in vivo studies of TSPO in humans.
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Chapter 2
Methods
2.1 Research participants
This thesis includes subjects that participated in different PET projects at KI (Study
I-VIII), as well as subjects examined at PET centers in the UK, USA and Canada
(sub-samples included in Study VI and VIII). All subjects included in the thesis gave
written informed consent according to the Helsinki declaration prior to participating.
All studies performed at KI were approved by the Stockholm regional ethics board
and the Karolinska Hospital radiation safety committee. Table 2.1 outlines the
demographic data for all studies and participants in this thesis.
Study I and Study II The subjects included in Study I (n = 23) and II (n =
26) were healthy controls examined with [11C]SCH23390. In addition to the PET
examinations, all participants were given personality questionnaires to fill out. A
subset of subjects included in Study II underwent two PET examinations as part of
a test-retest study (n = 16) that has been published previously (113 ), but only data
from the first examination was included in this thesis.
Study III Twenty-eight subjects (16 healthy controls and 12 patients with SAD)
were examined using [11C]FLB457. The patients were medication-free at the time of
PET. Eleven patients were examined prior to participating in a study about internet
based cognitive behavioral therapy for SAD (114 ).
Study IV Sixteen drug-naive first episode psychosis patients and 16 control subjects
were examined with [11C]PBR28. Patients were recruited from hospital wards and
outpatient clinics around the Stockholm region. Mean duration of illness was 7.9 ±
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9.6SD months. None of the patients had been exposed to anti-psychotic medication
and in order to ease participation, anxiolytics and sedatives were allowed during the
course of the study. Subsequently, 5 patients received occasional benzodiazepines.
Fourteen of the controls also participated in a [11C]PBR28 test-retest study (partly
overlapping with the sample used for Study V) and two controls were obtained from
different ongoing [11C]PBR28 study where they also participated as control subjects.
Study V Data from an already published [11C]PBR28 test-retest study (87 ) was
reanalyzed. Fourteen subjects were recruited to the original study, but for two subjects
data from the first PET examinations had to be discarded due to technical reasons.
The remaining 12 (6 HABs and 6 MABs) participated in two PET examinations
taking place on either the same day (n = 6) or 2-5 days apart (n = 6).
Study VI This study was an individual participant data (IPD) meta-analysis of
all published studies up to 2017 that examined TSPO binding in schizophrenia or
psychosis using second-generation radioligands. All participants from Study IV were
included, as well as an additional 28 subjects (14 patients, and 14 controls) (93 ), 30
subjects (14 patients and 16 controls) (115 ), and 68 unique subjects (35 patients
and 33 controls) (97,99 ).
Study VII Data from an already published (R)-[11C]PK11195 test-retest study
(85 ) was reanalyzed. Six healthy controls were examined with the first generation
TSPO radioligand (R)-[11C]PK11195 and underwent two PET examinations with
approximately 6 weeks in between.
Study VIII Different samples of healthy subjects examined with [11C]PBR28 were
included: A) 11 out of 12 subjects from the test-retest used in Study V (excluding
one subjects who’s second PET was only 60 minute long), B) 54 subjects from the KI
[11C]PBR28 database and C) 5 subjects that participated in a previously published
pharmacological competition challenge with XBD173 at IMANOVA Ltd London,
UK (116 ).
2.2 Personality assessment
In Study I and II, participants were given the Swedish universities Scale of Personality
(SSP) (117 ) to fill out. The SSP is a self-rating questionnaire that measures 13
different personality traits using scales consisting of 8 items each. Respondents rate
how much they agree with statements about their thoughts, behavior and emotions
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Table 2.1: Demographic data for all samples included in the thesis. f = females; m
= males
Study
and subsample Radioligand Target
N
total
N controls
f/m
N patients
f/m
Age controls
Mean (SD)
Age patients
Mean (SD)
Study I
- [11C]SCH22390 D1R 23 10/13 -/- 39.2 (21.9) -
Study II
- [11C]SCH22390 D1R 26 0/26 -/- 26.2 (3.2) -
Study III
- [11C]FLB457 D2/D3R 28 7/9 7/5 37.8 (15.2) 33.8 (11.6)
Study IV
- [11C]PBR28 TSPO 32 9/7 5/11 26.4 (8.4) 28.5 (8.4)
Study V
- [11C]PBR28 TSPO 12 6/6 -/- 23.9 (2.9) -
Study VI
All - TSPO 152 35/42 24/51 35.4 (15.1) 33.9 (12.6)
Bloomfied et al., 2016 [11C]PBR28 TSPO 26 3/11 3/9 46.2 (13.6) 47 (9.3)
Collste et al., 2017 [11C]PBR28 TSPO 32 7/9 8/8 26.4 (8.4) 28.5 (8.4)
Coughlin et al., 2016 [11C]DPA713 TSPO 26 5/9 3/9 25.4 (4.9) 24.3 (3.3)
Hafizi et al., 2017 [18F]FEPPA TSPO 37 10/8 7/12 27.3 (9.1) 27.5 (6.8)
Kenk et al., 2015 [18F]FEPPA TSPO 31 8/7 6/10 54.3 (9.5) 42.5 (14)
Study VII
- (R)-[11C]PK11195 TSPO 6 0/6 -/- 25.8 (3.9) -
Study VIII
KI [11C]PBR28 database [11C]PBR28 TSPO 54 22/32 -/- 45.2 (17) -
Test-Retest [11C]PBR28 TSPO 11 5/6 -/- 24.5 (3) -
XBD173 competition [11C]PBR28 TSPO 5 0/5 -/- 25.2 (7.3) -
over time and different contexts. Subjects respond by choosing one alternative on
a 4-point Likert-scale ranging from “Strongly agree” to “Strongly disagree”. The
measured personality traits are assumed to be semi-stable over time and different
contexts. They are thought to predict how vulnerable a person is for developing a
psychiatric condition (118,119 ). The SSP is an updated version of the Karolinska
Scale of Personality (120 ). It shows improved psychometric properties compared
to its predecessor, such as higher internal reliability and a more coherent factor
structure (117 ).
In Study I, three different SSP scales were considered: Social Desirability, Physical
Trait Aggression and Verbal Trait Aggression. The Social Desirability scale assesses
how a person represents herself in a social situation in order to gain approval and
acceptance by others. The Physical Trait Aggression and Verbal Trait Aggression
scales measures the tendencies of a person to react with physical violence or
intimidation when provoked or unfairly treated. Study II aimed to replicate the
findings from Study I, and only the Social Desirability and Physical Trait Aggression
scales were analyzed.
33
2.3 Radioligands
In Study I and II, [11C]SCH23390 (22 ) was used. [11C]SCH23390 has high affinity
for the D1-R (121 ).
In Study III, [11C]FLB457 was used. [11C]FLB457 is an analogue of epidepride and
has very high affinity for D2 and D3 receptors (D2/D3-R), making it a suitable
radioligand for examining binding outside the striatum where the density of D2-R is
lower (122 ).
In Study IV, V and VIII, the second-generation TSPO radioligand [11C]PBR28 (123 )
was used and in Study VII the first-generation TSPO radioligand (R)-[11C]PK11195
(124 ) was used. Both bind to the TSPO receptor (also known as the peripheral
benzodiazepine receptor), although [11C]PBR28 has tenfold the affinity for TSPO
compared to (R)-[11C]PK11195 (123,125 ).
Study VI included participants examined with three different second-generation
TSPO radioligands: [11C]PBR28, [11C]DPA713 (126 ) and [18F]FEPPA (84 ).
2.4 PET image acquisition
All participants included in studies performed at KI were examined with either the
ECAT Exact HR (Study I-II and VII) or the ECAT Exact HRRT (Study III-VI
and VIII) PET system at the KI PET center, located at the Karolinska University
Hospital in Solna, Stockholm. The HR system provides a transaxial field of view
of ~4 mm full width at half maximum (FWHM) (127 ). HR data was reconstructed
using filtered back projection with a Hann filter of 2mm cut off frequency. The HRRT
system provides transaxial field of view of ~2 mm FWHM (128 ). HRRT data was
reconstructed using 3D ordinary Poisson ordered subset expectation maximization
(10 subsets, 16 iterations), including modeling of the system’s point spread function
(129 ).
For all examinations, the radioligand was delivered as a rapid bolus, with an injection
time that ranged between 5-10 seconds. Transmission scans were performed prior
to all emission scans to correct for attenuation. To minimize movement during the
KI PET examinations, a plaster helmet was made for each participant and used to
fixate the head during the scan (130 ). In Study I and II the total emission scan was
51 minutes ([11C]SCH23390), in Study III 87 minutes ([11C]FLB457), in Study IV
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and V 90 minutes ([11C]PBR28), in Study VII 60 minutes ((R)-[11C]PK11195), while
in study VIII 75 minutes ([11C]PBR28) of the examinations were used. In all studies,
brain radioactivity was measured in a series of consecutive frames. To further correct
for head movement, all frames were realigned to the first minute of acquisition (131 ).
2.5 Arterial blood sampling
In Study IV, V, VII and VIII, blood samples were obtained using an arterial catheter.
The radioactivity levels in blood were then measured using an automated blood
sampling system (ABSS, Alogg Technology, Mariefred, Sweden). Only ABSS data
collected for the first 5 minutes of the examination was used. From the start to the
end of the scan, manual blood samples were also drawn at subsequent time points.
Samples of plasma were obtained by centrifugation of a subset of manual blood
samples. Radioactivity levels in these blood and plasma samples were measured in
a well counter. Plasma curves were derived by multiplying the blood curves with
plasma-to-blood radioactivity ratio values. Curves of the remaining parent fraction of
radioligand in plasma were obtained using high-performance liquid chromatography.
The plasma curves were then corrected for metabolites by multiplying them with
the parent fraction curves. These metabolite-corrected plasma TACs were then used
as AIFs in the kinetic modeling.
2.6 Definition of regions of interest
All participants included in this thesis underwent MRI scans and in order to derive
structural T1 weighted MR images. For studies carried out at KI, three different
MRI systems were used. All subjects in Study I were examined using the 1.5T
GE Signa system (Milwaukee, WI). Subjects in Study II and VII were examined
using the 1.5T Siemens Magnetom Avanto system (Erlangen, Germany). Subjects
in Study III were examined using either the 1.5T GE Signa (all patients and six
healthy controls) while the remaining controls (n=10) were examined using a 3T
GE Signa (GE MR750, GE Medical Systems, Milwaukee, WI, USA). All subjects in
Study VI, V and VIII were examined using the 3T GE Signa.
ROIs were then deliniated on the T1 weighted MR images. In Study I, striatal
ROIs were manually drawn using previously published guidelines (132 ), while the
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extrastriatal ROIs were delineated using the FreeSurfer software (version 5.0.0,
http://surfer.nmr.mgh.harvard.edu/). In all remaining studies carried out at KI, all
ROIs were automatically defined using either the FMRIB FSL software (133 ) (Study
II) or FreeSurfer (Study III-V, VII and VIII).
A manually delineated cerebellum was used as reference region in Study I and III.
Remaining studies that included a reference region used either a FreeSurfer (Study
V and VII) or FSL (Study II) defined grey-matter cerebellum, or the FreeSurfer
whole-brain ROI (Study V).
Following ROI delineation, all T1 weighted MR images were co-registered to the
PET images. In Study I-II, IV-V and VII-VIII TACs of radioactivity concentration
were then extracted for all ROIs.
2.7 Kinetic modeling
In this thesis, three different kinetic models have mainly been used to estimate
radioligand binding to target: the unconstrained 2TCM, SRTM (28 ), and the
non-invasive Logan plot fitted with a multilinear regression (134,135 ).
For all studies involving the [11C]PBR28 or (R)-[11C]PK1195 radioligands (Study
IV-VIII), the unconstrained 2TCM with AIF was used. For each subject and ROI, a
VT value was derived. Although VT, in theory, should have lower signal-to-noise ratio
(SNR) than e.g. VS, it is still widely applied as outcome measure. This is because VT
often show higher reliability and less variability compared specific binding outcomes
obtained from the 2TCM (136,137 ). Hence, in Study IV and VI, the VT values were
used to compare patients with psychosis or schizophrenia to healthy control subjects.
In Study I and II, the SRTM was used with cerebellum as reference region, yielding
ROI [11C]SCH23390 BPND values. These BPND values were then correlated with
SSP scale scores, to examine the relationship between pro and anti-social personality
traits and D1-R availability in striatum and extrastriatal regions.
2.7.1 Pseudo-reference region and supervised cluster-analysis
When non-negligible levels of target are expressed throughout the brain, it is not
possible to establish a true reference region. For example, in the case of [11C]FLB457,
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the radioligand can be displaced in the cerebellum, which suggests the presence of
specific binding (138,139 ). In the case of [11C]PBR28 and (R)-[11C]PK11195, TSPO
is expressed throughout the brain and there is no region that show even small levels
of uptake. When this is the case, it might still be possible to use a region as a
“pseudo-reference region”, but only under the assumption that the availability of
target in this region does not differ between the groups that are being compared,
or that the difference is minuscule. In Study III, which compares SAD patients to
healthy control subjects, [11C]FLB457 BPND values were derived using the cerebellum
as pseudo-reference region.
For (R)-[11C]PK11195, the cerebellum has also been suggested to function as a
suitable pseudo-reference region. The SRTM, with cerebellum as reference input,
has hence been used in many clinical studies, such as comparisons between controls
and patients with schizophrenia or psychosis (79–81 ). It is however unclear if this
is a sensible approach, since 1) the radioligand uptake is cerebellum is very high,
2) there is little to no evidence that the cerebellum be spared of pathology in any
psychiatric disorder, and 3) it has not yet been established if the resulting BPND
values are reliable.
Another alternative approach to quantify (R)-[11C]PK11195 expression in the brain,
without the need for arterial sampling, is to use SVCA4 method (96 ). The SVCA4
method is performed on brain-masked dynamic PET images and aims to segment the
voxels into different classes characterized by distinct kinetic profiles: 1. grey-matter
with high specific binding 2. grey-matter with low specific binding, 3. white-matter,
4. soft tissue. In order to do so, the method compares voxel TACs with a set of
pre-defined kinetic classes, derived from healthy subjects or a sample of subjects
thought to have inflammated brain tissue (95 ). The goal is to identify all voxel
TACs most similar to the kinetic class assumed to contain negliable levels of specific
binding. These voxels are then combined into a ROI from where a TAC is extracted
that can function as reference input to a kinetic model.
In Study VII, (R)-[11C]PK11195 BPND values were derived using SRTM with either
cerebellum or SVCA4 grey-matter TAC as reference input. The test-retest reliability
and convergent validity of these BPND values were then evaluated.
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2.7.2 Parametric imaging
In Study III, a BPND value was calculated for each voxel in the brain, using cerebellum
as pseudo-reference region. The HRRT yields PET files that consist of about 2 million
voxels, and using a non-linear model to fit each voxel TAC (such as the SRTM)
would take considerable amounts of time. Instead, the non-invasive multilinear Logan
analysis (134,135 ) was employed:
∫ t
0
CT (τ)d(τ) = DV R
(∫ t
0
CR(τ)d(τ) +
CR(t)
k′2
)
+ bCT (t) (2.1)
where CT is the concentration of radioligand in the target ROI, and CR is the
concentration in the reference region. The original non-invasive Logan graphical
analysis yields a plot of data which become linear after pseudo-equilibrium has been
reached (t*). In Study III, t* was set to 27 minutes. From t* to the end of the
examination, a linear regression model can be fitted, and the regression-coefficient of
the first predictor in equation 2.1 is the estimated distribution volume ratio (DVR
= VT/VND). Subtracting one from this parameter yields the BPND estimate for the
voxel of interest. Applying the Logan analysis to all voxels in the brain in Study III
yielded a parametric map of [11C]FLB457 BPND values for each participant.
Since there is substantial amount of noise in each individual voxel TACs, the voxel-wise
estimation of BPND becomes prone to error. For this reason, many different methods
for noise-reduction have been developed for parametric imaging in PET (140 ). In
Study III, the 3D stationary wavelet transform approach was used, as it has shown
to effectively reduce noise for [11C]FLB457 imaging (134 ).
In Study III, the final parametric maps of BPND were used to both apply statistical
parametric mapping (SPM) analysis on voxel-level, and extract mean voxel BPND
values using larger ROIs, in order to compare SAD patients with control subjects.
2.7.3 Ratio-based outcome measures
If arterial samples of radioactivity have not been collected, and no reference region
exist, the commonly applied outcome measure for radioligand uptake is ROI SUV.
However, the SUV has some critical limitations: 1) it often show large variability
and 2) it contain signal that is not related to the true density of the target, such
as radioactivity contribution from vasculature. Using SUV as outcome also relies
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on the assumption that there are no differences in radioligand delivery to the brain
between the individuals or groups that are being compared.
In order to reduce the high variability and low sensitivity of outcomes from
[11C]PBR28 studies without arterial blood samples, it has been suggested that ROI
SUVs can be divided or normalized by a SUV stemming from a pseudo-reference
region. The idea is that this would yield more reliable outcomes measure with
higher sensitivity to detect effects (91,92 ). [11C]PBR28 VT values, obtained by using
AIFs, also show large variability even after accounting for differences in the TSPO
affinity genotype. VT values have therefore also been suggested to benefit from being
normalized by VT from a pseudo-reference region, such as the cerebellum, occipital
cortex or the whole-brain (92,141 ).
In Study V, SUVRs and “distribution-volume-ratios” (DVRs) were derived by dividing
target ROI SUV or VT values by the SUV or VT from the whole-brain. The test-retest
reliability and convergent validity of the ensuing ratios were then evaluated.
2.7.4 Simultaneous estimation
The simultaneous estimation (SIME) technique aims to model TACs from several
brain regions simultaneously to estimate a brain-wide VND value for a subject (142 ).
This is done by replacing the rate constant K1 in equation 1.4 with VND · k2. A
unique k2 is then fitted for each ROI, but VND is constrained to be the same across
all ROIs for a subject. A set of different VND values are then evaluated for each
subject, and the value that results in the best fit across all ROIs is taken as the
final brain-wide estimate of VND. This value (VND:SIME) can then be used to derive
outcome measures of specific binding:
BPND =
VT − VND:SIME
VND:SIME
(2.2)
VS = VT − VND:SIME (2.3)
where VT is calculated using the unconstrained 2TCM.
In Study VIII, the accuracy and reliability of the SIME method applied on
[11C]PBR28, were evaluated. First, simulations were used to examine if SIME could
estimate an known “true” value of VND. Second, data from an already published
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pharmacological challenge study (116 ) was re-analysed to compare estimates of
VND using SIME, the revised Lassen plot (143 ) and the Likelihood Estimation
of Occupancy (144 ) techniques. Third, the test-retest data used in Study V was
re-analysed to examine the reliability and precision of SIME derived BPND and VS
values.
2.8 Statistical analyses
2.8.1 Correlations and replications
In Study I and II, Pearson’s correlation coefficients were used to examine the
relationship between SSP scale scores and [11C]SCH23390 BPND in the ROIs. In
Study I, partial correlations were used, with age and gender as covariates.
Study II was a direct replication attempt of the relationships found in Study I. First,
Pearson’s r were employed to assess if these relationships were significant in a new
and independent data set. However, since a p-value in itself does not convey much
information on how successful a replication is, Study II also employed a procedure
known as replication Bayes factor (BF). The replication BF examines how much
support there is in data for the original finding (H1), relative to a correlation of zero
(H0) (145 ). BF is the extent to which data updates the prior odds of two competing
models, to posterior model odds (104 ). As such, it can be used as an estimate of
how much support (or evidence) there is in data for one hypothesis over another.
For the correlation replication BF, H1 was defined as the posterior distribution of
the correlation coefficient from the original study (calculated using a uniform prior),
and H0 was defined as a point null hypothesis of no effect (146 ). A BF above 3 is
commonly interpreted as providing moderate support for one hypothesis over the
other, and a BF above 10 as strong support. Hence, if BF10 = 10, this means that
the observed data is 10 times more likely under the original hypothesis compared to
the null, signifying strong evidence in favor of a successful replication.
2.8.2 Patient-control differences
In Study III, multiple univariate two-tailed one-way independent samples ANCOVAs
were used to assess patient-control differences in extrastriatal [11C]FLB457 BPND,
while covarying for age.
40
In Study IV, a two-tailed one-way independent samples ANCOVA was used to assess
patient-control differences in whole grey-matter [11C]PBR28 binding, while covarying
for TSPO genotype and gender. In the article (147 ), four additional ROIs were
examined: frontal cortex, temporal cortex, hippocampus and whole white-matter.
Due to the high interregional correlations in VT only the results from grey-matter
are presented in this thesis.
The ANCOVA models used in Study III and IV are similar to an independent samples
t-test (i.e. two group means are being compared), with the addition of allowing
covariates to be entered into the model.
In Study VI, Bayesian linear mixed-effects models were used to assess patient-control
differences in TSPO levels, while taking into account the hierarchical and nested
structure of data. Four different models of increasing complexity were evaluated,
where PET center and TSPO genotype were entered as random effects, allowing
intercepts and slopes to vary. The model with the best out-of-sample deviance was
selected and used to assess patient-control differences. Bayesian hypothesis testing,
using BFs (148,149 ), was employed to assess the evidence in favor of patients with
psychosis having higher or lower TSPO binding, compared to control subjects. BFs of
standardized patient-control differences in VT were computed using the Savage-Dickey
Ratio (150 ).
The study design and statistical modeling of Study VI were pre-registered prior to
performing any literature search or analysis of data. The pre-registration protocol
can be found on https://github.com/pontusps/TSPO_psychosis.
2.8.3 Test-retest metrics
In Study V, VII and VIII, test-retest properties of radioligands and quantification
methods were evaluated using a set of different metrics. The absolute variability
(AbsVar) is an estimate of repeatability and was calculated by the following formula:
AbsV ar =
( |PET1− PET2|
(PET1 + PET2) /2
)
× 100 (2.4)
where PET1 is the ROI outcome measure (such as VT or BPND) in the first PET
examination, and PET2 is the ROI outcome measure in the follow-up examination.
As such, AbsVar is a measure of absolute percentage change. A value of 0 indicates
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that there has been no change between test and retest, and a value of 100 indicates
that the change is as large as the mean of both PET examinations.
The intra-class correlation coefficient (ICC) is an estimate of the reliability or
differentiability of subjects. It aims to calculate the proportion of variance that is
due to “true” signal of the total signal (true + error):
ICC = MSB −MSW
MSB +MSW
≈ σtrue
σtrue + σerror
(2.5)
where MSB is the between subjects mean sum of squared variance and MSW is the
within subjects mean sum of squared variance. An ICC of e.g. 0.5 indicates that
only half of the variance of the outcome measure is due to “true” signal, while the
remaining is due to error. According to previously suggested guidelines (151 ), an
ICC between 0.5 and 0.75 should be interpreted as indicating poor to moderate
reliability, 0.75 to 0.9 as good, and above 0.9 as excellent and suitable for usage in
clinical applications.
The standard error of measurement (SEM) (152 ) is related to the ICC but reflects
the precision of individual scores in the same unit of the outcome measure:
SEM = SD
√
1− ICC (2.6)
where SD is the standard deviation of the sample. The SEM can be thought of
as estimate of the standard deviation around each point-estimated outcome value.
E.g. if BPND for a subject is 1, and the SEM is 0.5, we expect 68% of all follow-up
measures to, on average, fall within 1± 0.5 assuming that the true density of target
is kept constant. The SEM can be recalculated to the minimal detectable differences
(MD) metric:
MD = SEM × 1.96×√2 (2.7)
This translates the SEM into the difference between two measurements that is
considered sufficiently large in order for the points to be significantly different from
each other, according to 95% confidence interval. A small MD indicates that the
outcome measure is precise, and that it will be easier to detect a difference between
two subjects, or two time-points, compared to an outcome showing a large MD. The
MD is often scaled so that it is expressed as percentage of the sample mean of the
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outcome measure. This is done to aid comparison between different outcomes.
2.9 Statistical disclosure statements
When studies lack pre-registration protocols it can be difficult for the reader to
assess how much evidential value the reported results contain, due to potential use
of intended and non-intended questionable research practices (153 ). In order for the
reader of this thesis to be able to better judge the robustness of the inference reported
in the included studies, this section presents statistical disclosure statements. The
following is a transparent listing of all analytical choices carried out in the studies,
but not reported in the published articles.
Study I Additional statistical analyses were performed as part of this study. First,
additional personality scales were analyzed (all extroversion and agreeableness
sub-scales from the NEO-PI-R inventory). Second, 6 additional subjects were
initially included but later excluded from the study due to the time interval between
PET and personality assessment being too long, which is reported in the article.
However, additional statistical analyses were also run with these subjects included,
and this was not reported. Third, all reported correlations had been run both with
and without controlling for gender and age. Forth, a Statistical Parametric Mapping
(SPM) analysis was performed but not reported in the final version of the article.
Study III Additional statistical analyses were performed as part of this study. First,
age as a covariate in the main ROI based and voxel-based analysis was not included
in the initial analysis but added at a later stage. Second, two additional subjects
were initially included in the healthy control group but later found to be taking
diabetes and SSRI medication respectively, and therefore excluded from the study.
The family-wise error rate correction method was additionally tried out to correct
for multiple comparisons on voxel-level but results from this were not reported.
Study II and IV-VII All statistical analyses that were performed have been
reported in the articles. All data from all subjects that was planned to be part of
the studies has been included and reported, unless otherwise stated in the articles.
However, in Study VI, two additional analyses that were not in the pre-registration
protocol were performed following requests from reviewers. These deviations have
been time-stamped and logged together with the pre-registration protocol (see
https://github.com/pontusps/TSPO_psychosis).
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2.10 Data and code availability
Study I The data has not been made publicly available due to current institutional
regulatory restrictions.
Study II All derived data (e.g. individual BPND values and personality scores) and
code used for Study II can be found on https://osf.io/te5q7/.
Study III The data has not been made publicly available due to current institutional
regulatory restrictions. However, data extracted from Figure 3.3 can be found on
https://osf.io/2jm9h/. The original code for reproducing the statistical analysis was
not saved at the time of the study.
Study IV The data has not been made publicly available due to current institutional
regulatory restrictions. However, data extracted from Figure 3.6 can be found on
https://osf.io/2jm9h/. The original code for reproducing the statistical analysis was
not saved at the time of the study.
Study V All derived data (e.g. TACs and genotype information) and code is available
on https://github.com/mathesong/PBR28_RatioMethods.
Study VI The majority of data used in this study was not collected by the authors,
and the first author does not have permission to share it publicly. However, data
extracted from Figure 3.9, and code for performing the main analysis of the study
can be found on https://osf.io/2jm9h/.
Study VII All derived data (e.g. TACs) and code is available on https://osf.io/
gcn4w/.
Study VIII The majority of data used in this study was not collected by the
authors, and the first author does not have permission to share it publicly. The
code for executing the main model evaluated in the article can be found on https:
//github.com/martinschain/SIME.
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Chapter 3
Results and Discussion
3.1 Overview
In this thesis, several different radioligands and quantification methods have been
implemented, evaluated and applied on clinical data.
Study I and II examined the relationship between D1-R availability and self-rated
pro and anti-social behavior in healthy subjects. Study I found a positive correlation
between striatal D1-R availability and Social Desirability, and a negative correlation
to Trait Aggression. Study II did however fail to replicate these results.
In Study III, D2-R availability in limbic and cortical regions in patients with SAD
and healthy controls were compared using both ROIs and voxel-wise analyses. SAD
patients were found to have higher D2-R availability in the DLPFC and OFC,
although the results warrant replication in a larger sample.
In Study IV, TSPO expression in the whole of grey-matter in patients with
first-episode psychosis and healthy controls were compared, and patients were found
to have lower TSPO binding.
In Study V the test-retest reliability and convergent validity of alternative ways
to measure [11C]PBR28 binding were evaluated. DVRs and SUVRs, derived using
pseudo-reference regions, showed both poor reliability and convergent validity.
Study VI carried out a meta-analysis of TSPO expression in patients with
schizophrenia and psychotic disorders compared to healthy controls. Strong evidence
was found in favor of patients having lower TSPO binding in both cortical and
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subcortical regions.
In Study VII the test-retest reliability and convergent validity of alternative ways
to estimate (R)-[11C]PK11195 binding were evaluated. BPND values, derived using
pseudo-reference TACs with the SRTM, were unreliable and showed no convergent
validity to outcomes derived using AIFs.
Finally, Study VIII aimed to evaluate the reliability and accuracy of a new modeling
method to estimate specific [11C]PBR28 binding without requiring a reference region.
Simulations, a pharmacological challenge and test-retest data showed that VND and
ensuing VS values derived using this method, were accurate, precise and reliable.
3.2 Study I
Study I explored relationships between [11C]SCH23390 BPND in a set of ROIs and
SSP Social Desirability, as well as Physical and Verbal Trait Aggression scale scores
(Table 3.1). Social Desirability was positively correlated to D1-R availability in all
striatal regions, when controlling for age and gender (using an uncorrected alpha
threshold of 0.05). Physical Trait Aggression showed a negative relationship to D1-R
availability in the limbic striatum, while Verbal Trait Aggression was not related
to BPND in any ROI. In extrastriatal regions, Social Desirability showed significant
positive correlations with D1-R availability in amygdala and medial frontal cortex,
after using the “p-plot” method (154 ) to correct for multiple comparisons (Table
3.1).
The results from Study I should however be considered exploratory and not
confirmatory. The reasons for this are that additional statistical analyses were
performed but not presented in the study (see section on Statistical Disclosure
statements in Methods), and because the alpha threshold was not adjusted for
multiple comparisons for the striatal ROI analyses. The results hence carry
limited evidential value. Instead, they can be thought of as hypothesis-generating:
[11C]SCH23390 BPND in the limbic striatum will be positively correlated to the
pro-social personality trait Social Desirability, and negatively correlated to anti-social
traits, such as aggression.
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Figure 3.1: Example of ROI delineation in Study I (manually drawn on an individual
T1-weighted MR image) and II (defined using the FSL Oxford-GSK-Imanova
connectivity atlas of striatum). In Study I the limbic striatum is depicted in green,
and in Study II in yellow. The bottom panel displays an average [11C]SCH23390
BPND brain map from all subjects in Study II.
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Table 3.1: Pearson’s partial correlations (controlling for age and sex) between D1-R
availability and personality traits reflecting pro and anti-social behavior. Alpha was
set to 0.05, uncorrected for striatal regions and family-wise-error rate corrected for
extrastriatal regions. LST = limbic striatum; AST = associative striatum; SMST
= sensorimotor striatum; ACC = anterior cingulate cortex; HIP = hippocampus;
INS = insula; MFC = medial frontal cortex; LFC = lateral frontal cortex; OFC =
orbitofrontal cortex
Region Social Desirability Physical Trait Aggression Verbal Trait Aggression
r p df r p df r p df
Striatal ROIs
Striatum 0.54 0.012 19 0.36 0.106 19 0.13 0.578 19
LST 0.52 0.015 19 0.51 0.019 19 0.37 0.101 19
AST 0.55 0.009 19 0.31 0.165 19 0.09 0.700 19
SMST 0.67 0.001 19 0.35 0.120 19 0.02 0.926 19
Extrastriatal ROIs
ACC 0.51 0.018 19 0.55 0.010 19 0.29 0.199 19
AMG 0.60 0.006 18 0.41 0.072 18 0.24 0.316 18
HIP 0.49 0.033 17 0.46 0.048 17 0.50 0.028 17
INS 0.47 0.031 19 0.50 0.021 19 0.46 0.038 19
MFC 0.60 0.004 19 0.39 0.077 19 0.17 0.461 19
LFC 0.55 0.010 19 0.35 0.117 19 0.01 0.955 19
OFC 0.53 0.013 19 0.50 0.020 19 0.19 0.398 19
3.3 Study II
Study II aimed to replicate and confirm the exploratory findings from Study I.
The relationships between Social Desirability and Physical Trait Aggression and
[11C]SCH23390 BPND in whole-striatum and, in particular, the limbic striatum were
deemed to be most interesting and carry the highest chance of replicating. Hence,
these relationships were analyzed using Pearson’s r and replication BFs in a new and
independent sample of subjects (Figure 3.2).
The results showed that none of the correlations between personality scale scores
and D1-R availability were significant (Figure 3.2). Instead, replication BF revealed
that there was moderate to strong evidence in favor of failed replications. The data
supported to null-hypothesis up to 12 times more than it supported the original
findings from Study I (Table 3.2).
In conclusion, the results of Study II did not confirm the exploratory findings from
Study I. Instead, the results indicated evidence in favor of no correlation between
D1-R availability and pro and anti-social personality traits, as measured using the
SSP. A potential reason for this failed replication is that a more diverse sample
was used in Study I, and the subsequent loss of variance in Study II meant that
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Table 3.2: Correlations between Social Desirability and Physical Trait Aggression
scores and ROI [11C]SCH23390 BPND from Study I and Study II. The replication
BFs denotes how much support there is for a successful replication (BF10) compared
to that of no correlation (BF01). Note that the correlation between Physical Trait
Aggression and STR was not significant in the original study but has still been
included here for completeness. STR = whole-striatum; LST = limbic striatum
Original studya Present study b Replication BF
r df p-value r df p-value BF01 BF10
Social Desirability
STR 0.54 19 0.012 -0.12 24 0.73 12.4 0.08
LST 0.52 19 0.015 -0.03 24 0.57 7.2 0.14
Physical Trait Aggression
STR -0.36 19 0.106 -0.08 24 0.35 2.0 0.51
LST -0.51 19 0.019 -0.09 24 0.32 3.3 0.31
a two-sided test
b one-sided test in direction of original study
associations were difficult to detect. However, another likely explanation is that the
results in Study I were false positives and that there is no direct relationship between
striatal D1-R availability and Social Desirability or Trait Aggression in humans.
3.4 Study III
Study III examined the difference in extrastriatal [11C]FLB457 BPND between patients
with social anxiety disorder and healthy controls. Univariate ANCOVAs, controlling
for age, showed no significant patient-control differences in BPND in any of the the
ROIs (Figure 3.3).
Using the wavelet-aided parametric imaging approach (134 ), BPND values in each
voxel were calculated for each participant. These individual brain-wide voxel-maps
were normalized into the Montreal Neurological Institute standard stereo-tactical
space. All maps were then smoothed with a cubic Gaussian kernel (FWHM 8x8x8
mm). The ROIs presented in Figure 3.3 were concatenated into a brain mask that
was used in the SPM analysis of voxel-wise group differences (Figure 3.4).
An ANCOVA, controlling for age, revealed significant group differences (using false
discovery rate correction, FDR with alpha = 0.05) on voxel-level, with patients
showing higher BPND in multiple voxels in cortical regions compared to controls
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Figure 3.2: Relationships between [11C]SCH23390 BPND in striatum and Social
Desirability and Physical Trait Aggression. The dotted lines indicate the 95%
confidence intervals. Raw scale scores have been transformed to T-scores for
illustrative purposes in this figure.
(Figure 3.4). The FDR correction method does however come with an important
caveat: Contrary to FWEr correction, it does not control error rates in such manner
that the risk of obtaining any false positive voxel is, on average, set to 5%. Instead,
FDR correction sets the error rate so that, on average, not more than 5% of
significant voxels will be false positives. This entails that a small and confined cluster
of significant voxels could, in theory, all be false positives (155 ). For this reason,
FWEr correction on cluster-level was also employed in this study, revealing significant
differences in the OFC and right dorsolateral prefrontal cortex (DLPFC).
All patients (n = 12) and a subset of control subjects (n = 10) filled out the self-rating
version of the Liebowitz Social Anxiety Scale (LSAS-SR) (156 ) prior to participating
in the PET examination. There was no significant correlation between LSAS-SR
scores and voxel [11C]FLB457 BPND values within the pre-defined brain mask (results
not shown), after correction for multiple comparisons.
One important caveat with the study is that healthy control subjects showed
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Figure 3.3: Comparisons of [11C]FLB457 BPND values between 12 SAD patients
(SAD pat) and 16 healthy controls (HC) in cortical and subcortical ROIs. None of
the ROIs showed significant differences between the groups. There was a negative
correlation between age and BPND in all regions (here only LFC is shown), and age
was therefore included as covariate in the statistical analysis.
numerically higher SUVs in the reference region (cerebellum). The group difference
in SUVs was not significant (t=1.64, df=26, p=0.11, Cohen’s d=0.65), but a visual
inspection of the data (plot not displayed) showed that three control subjects had
substantially higher values compared to the remaining participants. SUVs are not
suitable as direct estimates of specific binding, but this result still suggest that
healthy control subjects might have higher specific uptake in the reference region.
This could in turn fully or partly cause the observed finding of lower BPND in control
subjects. However, when excluding the three healthy control showing higher SUVs in
cerebellum, the patient-control differences in cortical BPND still remained significant
in the SPM analysis, although with smaller effect sizes.
The results from Study III suggest that patients with SAD might have higher D2-R
availability in frontal cortex, compared to healthy controls. In SAD, a large part
of the experienced distress and avoidance behavior expressed by patients is likely
caused by anticipatory anxiety (46 ). OFC is essential for signaling expectations of
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Figure 3.4: In the two upper panels, average [11C]FLB457 BPND brain maps for
16 healthy control subjects and 12 social anxiety disorder patients (SAD pat) are
displayed. The ROIs were concatenated into a mask (A), which was then used
to restrict the voxel-wise group comparison. In the SPM analysis, SAD patients
expressed elevated levels of D2-R availability within bilateral orbitofrontal cortex
(B) and right dorsolateral prefrontal cortex (C).
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future outcomes, such as predictive representations of sensory input and emotional
valence (157 ). The region is also part of processing anticipatory anxiety by inflating
predictions of threats (158 ). These predictions are relayed to the DLFC, a region
shown to be responsible for signaling the mismatch between expectations and actual
sensory input, i.e. prediction errors (159 ). Prediction errors of aversive stimuli have
in turn been shown to be mediated by the midbrain dopamine system (160,161 ).
Hence, it can be speculated that an aberrant extrastriatal dopamine D2-R signaling
system in cortical regions is linked to critical disease mechanisms in SAD, such as
processing of fearful social stimuli or avoidance responses.
In addition to the group difference in cerebella SUVs, two caveats in this study were
that a small sample size was used, and that analysis plan was not pre-registered.
Another important limitation is that the smoothing of parametric PET images can
induce substantial amount of variability, especially on the edge of the fronto-cortical
surface. Hence, 3D smoothing can make cortical voxel BPND values unreliable and
prone to produce outliers (113 ). The findings from Study III therefore need to
be replicated in order to assess the robustness of the results. Preferable, such a
replication should be carried out in a much larger sample and using only ROIs.
3.5 Study IV
In Study IV, the TSPO levels in drug-naive patients with first-episode psychosis
(FEP) (n = 16, 11 male, 5 female, mean age = 28.5 ± 9.4SD) was compared to
healthy control subjects (n = 16, 7 male, 9 female, mean age = 26.4 ± 8.4SD)
using the whole grey-matter as ROI. TSPO expression is thought to function as
an index of microglial activation, which in turn is considered to indicate immune
activation in the brain. Hence, in line with the immune hypothesis of schizophrenia,
the hypothesis was that patients would show higher [11C]PBR28 binding compared
to controls. However, previous to this study, another article had just been published
reporting no differences in [11C]PBR28 VT between patients with schizophrenia and
controls. Instead, the effect size of difference suggested that patients might express
lower levels of TSPO in the whole grey-matter (93 ). For this reason, we employed a
two-tailed statistical test, examining group differences in VT both directions.
All patients were recruited from psychiatric wards and out-patient clinics in the
Stockholm region. At the time of the study, all patients were naive to anti-psychotic
medication. According to DSM-IV, they met the diagnostic criteria for schizophrenia
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Figure 3.5: Average summation PET image of 32 subjects examined with [11C]PBR28.
(n=4), schizophreniform psychosis (n=7), psychosis NOS (n=4) or brief psychosis
(n=1). During the course of the study, antidepressants as well as occasional medication
with sedatives and anxiolytics were allowed.
Two different outcome measure of TSPO expression in the brain were used:
[11C]PBR28 VT and DVR. DVRs were calculated by dividing the whole grey-matter
[11C]PBR28 VT with whole-brain [11C]PBR28 VT. The reason for including DVR
was because a previous study suggested that this outcome measure yielded higher
sensitivity to detect patient-control differences compared to VT (93 ). In that study,
the difference in DVR between patients with schizophrenia (n=14) or subjects with
high-risk of developing a psychotic disorder (n = 14) and healthy controls were
found to be of a very large effect size. Hence, Study IV aimed to replicate this
finding, using a slightly larger sample of patients.
Patient-control differences in whole grey-matter [11C]PBR28 VT and DVRs were
examined using an ANCOVA, controlling for gender and the TSPO genotype (patients
= 8 HABs and 8 MABs; controls = 9 HABs and 7 MABs). The alpha level was
set to 0.05. The patient group showed significantly lower [11C]PBR28 VT in the
whole-grey-matter ROI, compared to control subjects (F = 6.19, df = 1.28, P =
0.019). The difference between HAB patient-controls (η2 = 0.38) was larger than
that of MAB patient-controls (η2 = 0.02) (Figure 3.6). There was however no group
difference in [11C]PBR28 DVR (F = 0.07 df = 1.28, p = 0.80), using grey-matter
VT in the numerator and the whole-brain VT in the denominator (Figure 3.6). As a
result, this study did not replicate the previous finding of higher DVR in patients
(93 ).
Contrary to the hypothesis of higher TSPO levels in patients with psychosis, this
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Figure 3.6: Differences between FEP patients and healthy controls in [11C]PBR28
grey-matter VT and DVR values. DVRs were calculated by dividing VT in grey-matter
with VT in the whole-brain, to replicate the previous findings from Bloomfield et al.
(93 ).
study found the opposite pattern. FEP patients showed significantly lower levels of
[11C]PBR28 VT in grey-matter compared to controls. Despite a previosly reported
patient-control difference in grey-matter DVR of large magnitude (93 ), this study
found no difference in DVR between the diagnostic groups. Although the patients in
the previous study were medicated with anti-psychotics, it is unlikely that the lack of
an observed effect in the current study was due to medication-status since drug-naive
high-risk individuals also differed from controls in grey-matter DVR (93 ). However,
looking at Figure 3.6 it becomes clear that all DVR values are very close to one, and
that the variance between subjects has almost entirely been eliminated (DVR mean
of whole sample = 1.05 ± 0.036SD v.s. VT mean of whole sample = 3.2 ± 1.59SD).
When examining the effect sizes reported in the revised supplementary information
of the previosly published study (93 ), the difference in VT between patients and
controls seemed to be mostly confined to the denominator region and not the target
region.
In light of these concerns, and in order to aid interpretation of the contradictory
DVR findings from Study IV and Bloomfield et al. (93 ), we set out to evaluate the
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reliability, precision and validity of [11C]PBR28 DVR values.
3.6 Study V
The objective of Study V was to evaluate the test-retest reliability and convergent
validity of [11C]PBR28 ratio-outcomes. Specifically, the DVR and SUVR outcome
measures were investigated by re-analyzing an already published test-retest
[11C]PBR28 dataset (87 ). Twelve healthy subjects (mean age = 23.9 ± 2.99SD, 6
males, 6 females, 6 HABs, 6 MABs) had been examined twice with [11C]PBR28. The
examinations took place either on the same day (n = 6) or with 2-5 days apart (n =
6). Due to technical reasons, one individual had a shorter follow-up examination.
This subject was excluded from the test-retest analysis but the first examination
was included in all correlational analyses.
The cerebellum and whole-brain were used in the denominator of the ratio-outcomes,
as both have been suggested to be suitable pseudo-reference regions for [11C]PBR28
(91,93 ). The frontal cortex was selected as the primary target ROI in this study and
used in the numerator of the ratios. Frontal cortex was chosen instead of the whole
grey-matter in order to have at least one ratio-outcome (frontal-cortex/cerebellum)
that was not based on nested regions.
Figure 3.7 shows the interregional correlations for VT and SUVs. Frontal cortex,
cerebellum and whole-brain VT were highly correlated (all Pearson’s r > 0.98) for
both HAB and MAB subjects. A similar pattern was observed for SUVs, calculated
from 40-60 minutes (all Pearson’s r > 0.95).
Table 3.3 displays the test-retest metrics for all outcome measures evaluated in Study
V. Both frontal cortex VT and SUVs showed high reliability as estimated using
ICC. DVR showed poor reliability, with ~46-48% of the variance estimated as being
attributable to error. SUVR showed medium to high reliability. Both VT and SUV
showed higher variability, as compared to the ratio-based outcome measures. There
were no correlations between Frontal Cortex VT and SUVR or DVRs (Figure 3.8),
except for SUVRWB. However, examining at HABs and MABs separately revealed
that the relationship between SUVRWB and VT was confined only to MAB subjects
(HAB R2 = 0.01; MAB R2 = = 0.33). VT and SUV were however correlated to each
other (HAB R2 = 0.64; MAB R2 = 0.86, Figure 3.8).
[11C]PBR28 DVRs, calculated using either cerebellum or whole-brain VT in the
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Figure 3.7: Interregional correlations of [11C]PBR28 VT and SUV in frontal cortex
(FC), cerebellum (CER) and whole-brain (WB). HABs are depicted in orange and
MABs in blue.
denominator, showed poor reliability and no convergent validity to VT or SUVs.
SUVRs showed an apparent moderate to high reliability, but also lacked association
to SUV or VT. The most concerning finding for [11C]PBR28 ratio-based outcomes is
the high interregional correlations for VT and SUVs. Creating ratios out of outcomes
that correlate r>0.95 likely mean that little to no biological signal remains after the
division. Instead, the ensuing outcomes might reflect little else but measurement
error. In addition, due to these high interregional associations for VT and SUVs, the
inter-individual variance is almost entirely eliminated after division, and all subject’s
values are set to be close to one. This partly explains the low variability observed
for the ratio-outcomes. However, this also means that small changes specific to the
numerator or the denominator that are induced by methodological artifacts (such as
partial volume effects or head movement) can lead to very large differences in the
total outcome between individuals or groups.
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Table 3.3: Mean values, variability and test-retest metrics for VT , SUV, SUVR and
DVR using the frontal cortex as the target region and the cerebellum (CER) or
whole-brain (WB) as the denominator region for the ratio-based outcomes.
Genotype Denominator Mean SD ICC AbsVar SEM
VT from 2TCM
HAB - 3.90 1.64 0.89 21.0 14.0
MAB - 2.20 1.01 0.93 17.0 12.0
All CER 0.98 0.07 0.54 4.7 4.9
All WB 1.00 0.04 0.52 3.0 2.5
SUV 40− 60min
HAB - 1.10 0.24 0.76 13.0 11.0
MAB - 0.80 0.25 0.91 13.0 9.1
All CER 0.95 0.06 0.63 4.4 3.8
All WB 1.00 0.04 0.89 1.5 1.3
The findings of this study suggest that strong caution is warranted when interpreting
results from clinical [11C]PBR28 studies making use of ratio-based outcome measures.
This caution should especially be applied to studies including healthy control subjects,
or a patient group where there is little evidence of the pseudo-region being spared of
pathology that affect TSPO levels.
3.7 Study VI
Study V found that [11C]PBR28 DVR is unreliable and likely to reflect little to no
biological signal, suggesting that the previous finding of higher DVR in schizophrenia
(93 ) likely contained limited evidential value. The results from Study IV instead
suggested that patients with psychosis have lower levels of TSPO in the brain
compared to healthy controls, contrary to the hypothesis of an elevated microglia
activation in schizophrenia. During the course of Study IV, a set of studies was
published that also examined microglia activation in psychosis or schizophrenia using
second generation TSPO radioligands (97,99,115 ). In line with the results from
Study IV and Bloomfield et al. (93 ), none of these studies found the expected
elevation of brain TSPO levels in patients. However, all published studies, including
Study IV, used small sample sizes (all patient consisted of n < 20). The power
to detect a medium-sized difference (e.g. Cohen’s D ≈ 0.5 with an alpha = 0.05)
in VT between patients and controls ranged from 23% to 34% in previous designs
(93,97,99,115,147 ). This level of power severely limits any conclusion that can be
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Figure 3.8: Associations between frontal cortex [11C]PBR28 VT , SUV and ratio-based
outcomes, using the whole-brain and cerebellum as denominator regions. HABs are
depicted in orange and MABs in blue.
drawn these previous studies.
Hence, Study VI set out to perform an IPD meta-analysis (162 ) on all second
generation TSPO studies on psychosis or schizophrenia. The goal was to synthesize
all previously published data, and examine if patients showed no difference (H0),
higher (H1) or lower (H2) TSPO levels in the brain as compared to healthy controls.
A literature search on PubMed was performed to ascertain that all published second
generation TSPO studies on psychosis or schizophrenia were included. Inclusion
criteria for studies were that they 1) used a second-generation TSPO radioligand,
2) reported brain VT values in the in subjects with psychosis or schizophrenia as
compared to healthy controls, and 3) reported TSPO affinity type of all participants.
At the time of the search (June 2017) five published articles fulfilled these criteria.
The corresponding authors of all articles were contacted and all agreed to share
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the VT values, age, gender and TSPO genotype information, clinical ratings and
medication status for all individuals included in the original articles. The frontal
cortex, temporal cortex and hippocampus were selected as ROIs, as the majority
of articles reported VT values from these three regions. For Bloomfield et al. (93 ),
that did not report results from these regions, VT values derived from the 2TCM
were obtained and used in this meta-analysis.
The final sample amounted to 75 patients with schizophrenia or a psychotic disorder
(mean age = 33.88 ± 12.57SD; 52 HABs; 23 MABs) and 77 healthy controls (mean
age = 35.42 ± 15.12SD; 56 HABs; 21 MABs). To account for range and magnitude
differences in VT among the different radioligands used across studies, all ROI VT
values were standardized (z-scored) within each genotype group of each study (Figure
3.9).
Four different Bayesian linear mixed-effects models examining patient-control
differences in VT (∆VT ) were evaluated to account for the hierarchical structure
of data (Figure 3.10). In model 1 (M1) standardized ROI VT was specified as the
dependent variable, diagnostic group as the fixed effect, and genotype and study as
random effects allowing the intercepts to vary. M2 was identical to M1 but added
varying slopes of the random effect of genotype (i.e., allowing for differences in ∆VT
between HAB and MAB subjects). M3 was also identical to M1 but added varying
slopes of the random effect of PET center (i.e., allowing for differences in ∆VT
between included study samples). M4 allowed for varying slopes of both genotype
and PET center.
M1 showed the best fit to data, as determined by the leave-one-out cross-validation
fit procedure. Converting the fits of all models to Akaike Weights revealed that M1
showed only slightly better out-of-sample deviance compared to M2 and M3. M1
was therefore used to calculate BFs to evaluate the support for H0, H1 and H2 in
data. H1 was specified as a folded-normal distribution centered at zero with an SD of
0.5, expecting higher VT in patients. H2 was similarly specified but expecting lower
VT in patients. H0 was specified as the point null. M3, allowing the random slopes
of PET center to vary, was used to evaluate the between-sample heterogeneity and
produce forest-plots of ∆VT (Figure 3.11). In M3, the prior over ∆VT was specified
as a weakly regularizing normal distribution (mean = 0, SD = 10).
In all regions, BFs showed strong evidence in favor of H2 (patients having lower
TSPO levels) relative to H1 (patients having higher TSPO levels). BFs also indicated
strong evidence in favor of H2 compared to H0 (no group difference in TSPO levels).
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Figure 3.9: All IPD VT data included in the meta-analysis. All VT values have been
z-scored within study-sample and genotype to produce the pooled plots to the right
(the means of HAB and MAB subjects have hence been set to zero).
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Figure 3.10: Schematic show the included studies and hierarchical structure of data.
Bloomfield et al. (93 ) only included two MAB patients but no MAB control subjects.
These two subjects were excluded from the analysis since Z-scoring within genotype
group was not meaningful. The studies by Kenk et al. (97 ) and Hafizi et al. (99 )
shared 14 healthy control subjects. These subjects were allocated to either Kenk et
al. (97 ) or Hafizi et al. (99 ) in this IPD meta-analysis.
Hence, there was >422 times more support in data for the hypothesis of lower levels
of TSPO in patients as compared to higher levels. A robustness check of BFs revealed
that strong support in favor of H2 was maintained when varying the widths (SD =
0.2 and 0.8) of the prior distributions over H1 and H2.
The forest plot (Figure 3.11) revealed similar results. The overall patient-control
differences in standardized VT values were centered around -0.48 for frontal cortex,
-0.47 for temporal cortex and -0.64 for hippocampus, roughly corresponding to
medium-sized differences (163 ). The credible intervals did however show considerable
uncertainty around these point-estimates (Figure 3.11). Despite this, the posteriors
indicated that it is still unlikely that patients have higher levels of TSPO compared
to controls in any of the brain regions. The probability of e.g. temporal cortex ∆VT
being above zero (i.e. patients > controls) is only 0.013, conditioned on the data and
the model. M3 also showed low between-study heterogeneity (posterior mean = 0.23,
95% credible interval [0, 0.60]).
The results of Study VI suggest that there is strong evidence in favor of patients
with psychosis or schizophrenia having lower TSPO levels throughout the brain.
Assuming that TSPO binding is a suitable index of glial cell activity, this suggest
that patients have lower density, or altered function, of microglia in cortical and
subcortical regions.
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Figure 3.11: Standardized difference in TSPO levels (estimated using VT ) between
patients with psychosis or schizophrenia and healthy control subjects. The posterior
distribution for each study-specific difference in VT estimate (random slopes) from
the Bayesian linear mixed model (M3) is presented. The black circle denotes the
posterior mean, and the thick line denotes the 95% credible interval; these are also
presented in text next to the plots. The cross denotes the patient–control difference
in raw data (together with its 95% credible interval) without performing linear
mixed-effects modeling. Hence, the difference between the dot and the cross show
the model shrinkage toward the mean. The overall effect size suggest that patients
show lower TSPO levels in all three brain regions.
3.8 Study VII
Study VI only included studies using second-generation TSPO radioligands. A
set of studies have however examined patients with psychotic disorders using the
first generation TSPO radioligand (R)-[11C]PK11195 (77–81 ). In these studies, a
wide range of different outcome measures were used, such as VS or BPND derived
from 2TCM, BPND derived using SVCA or BPND derived using cerebellum as
pseudo-reference region. The reason for excluding these articles from Study VI was
as follows: in a meta-analysis model, all sample-specific effect sizes have to come
from the same underlying distribution of effects. Since very different quantification
methods and outcome measures had been used, it was unlikely that the effect
from these previous (R)-[11C]PK11195 studies could be synthesized into the same
model. However, peer reviewers of Study VI pointed out that BPND estimates
of (R)-[11C]PK11195 data were both precise and showed high sensitivity to detect
patient-control differences, and that the meta-analysis hence omitted an important
part of the literature. It was difficult to assess the credibility of such claims, as
there is to date no thorough evaluation of reliability, sensitivity and validity of
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Figure 3.12: Average (R)-[11C]PK11195 thalamus, cerebellum and SVCA4-reference
TACs. The metabolite corrected plasma curve (truncated at SUV = 37) is also
shown. All TACs are expressed in SUV units to allow for averaging.
(R)-[11C]PK11195 outcome measures used in previous psychosis studies.
Study VII hence set out to investigate the test-retest properties and convergent
validity of different (R)-[11C]PK11195 outcome measures. Specifically, the reliability
of BPND derived from the 1) 2TCM, 2) from using a SVCA reference TAC, and
3) from a pseudo-reference region (cerebellum) was evaluated (Figure 3.12). Study
VII also aimed to correlate these BPND estimates with VT and VS derived from the
2TCM using an AIF.
Data from six healthy subjects (mean age = 25.8 ± 3.9SD, all males) that
participated in an already published test-retest study (85 ) was re-analyzed. All
subjects performed two PET examinations, approximately 6 weeks apart. Frontal
cortex, whole grey-matter, hippocampus, striatum and thalamus were selected as
ROIs. VT, VS and BPND were calculated from rate constants extracted from the
2TCM. BPND values were also derived using the SRTM with cerebellum as reference
region, or by using a SVCA4-derived reference TAC.
The results showed that BPND values derived using cerebellum or a SVCA4 reference
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Figure 3.13: Correlations between the different (R)-[11C]PK11195 outcome measures.
Outcomes derived from using AIF were not correlated to outcomes derived without
AIF. BPND from the 2TCM was not correlated to any other outcome. All BPND
hence showed low convergent validity towards VT or VS from the 2TCM with AIF.
TAC were close to zero, or even negative (Table 3.4). The overall regional reliability,
as estimated using ICC and AbsVar, was poor for all measures of BPND derived with
or without an AIF. The precision, as estimated using SEM and MD, was also low.
VT and VS from the 2TCM did however show moderate reliability (Table 3.4).
Figure 3.13 shows the correlations between the evaluated outcome measures. None
of the BPND outcomes were correlated to VT or VS from the 2TCM (all R2 < 0.11).
VT and VS were correlated to each other, as were BPND using cerebellum and BPND
using a SVCA4 derived TAC as reference input.
The results from Study VII suggest that (R)-[11C]PK11195 BPND, estimated with or
without AIF, showed low reliability and poor precision. BPND was not correlated to
VT or VS, suggesting no to low convergent validity. Hence, if VT or VS, at least in
part, reflects true binding to target, it is unlikely that BPND estimates does so as
well. Rather, the results suggest that BPND estimates are so unstable and imprecise
that they might represent little more than noise. Previous (R)-[11C]PK11195 BPND
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Table 3.4: Mean values all subjects (R)-[11C]PK11195 PET examinations. The
rest-retest reliability, repeatability and precision were estimated using the Intra-Class
Correlation Coefficient (ICC), average absolute variability in percentage (AbsVar)
and standard error of measurement (SEM), of different outcome measures derived
with or without AIF. The minimum detectable difference (MD) denotes the difference
(expressed as a percentage of the mean) needed between two measurements for them
to be significantly different from each other.
Region Mean SD ICC AbsVar SEM MD
VT (2TCM)
FC 0.72 0.16 0.73 15 0.08 32
GM 0.70 0.17 0.78 15 0.08 31
HIP 0.72 0.19 0.66 21 0.11 44
STR 0.76 0.17 0.44 18 0.13 46
THAL 0.77 0.22 0.69 21 0.12 43
VS (2TCM)
FC 0.42 0.09 0.68 14 0.05 32
GM 0.42 0.09 0.67 15 0.05 34
HIP 0.45 0.10 0.35 21 0.08 51
STR 0.44 0.10 0.23 23 0.09 58
THAL 0.48 0.14 0.91 13 0.04 24
BPND (2TCM)
FC 1.49 0.33 0.65 18 0.20 37
GM 1.62 0.40 0.31 29 0.33 56
HIP 2.02 0.77 -0.19 50 0.84 115
STR 1.41 0.39 0.32 22 0.32 63
THAL 1.79 0.67 -0.11 39 0.71 110
BPND (SRTM-SVCA4)
FC 0.17 0.04 0.21 29 0.04 63
GM 0.21 0.06 0.34 27 0.05 59
HIP 0.17 0.09 -0.39 83 0.10 160
STR 0.21 0.09 -0.12 59 0.09 120
THAL 0.35 0.09 0.32 22 0.07 55
BPND (SRTM-CER)
FC -0.07 0.09 0.50 160 0.06 258
GM -0.03 0.06 0.51 277 0.04 444
HIP 0.01 0.08 0.19 181 0.07 1920
STR -0.02 0.17 -0.14 196 0.18 2963
THAL 0.09 0.06 0.67 494 0.04 112
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studies making use of BPND values derived from 2TCM, SVCA4 or the cerebellum
as pseudo-reference region should be interpreted with caution, at least when they
include healthy control subjects as a comparison group.
3.9 Study VIII
Study VII showed that direct estimates of specific (R)-[11C]PK11195 radioligand
binding (such as BPND) were unreliable and unlikely to be useful in clinical studies.
With regards to [11C]PBR28, BPND from the 2TCM has previously been shown to
be unreliable (87 ). For these reasons, VT was used to estimate TSPO levels in the
brain of patients with psychosis and control subjects in Study VI. VT does however
contain both specific (VS) and non-displaceable signal (VND) and is therefore not a
direct estimate of specific binding. The conclusions of Study VI relies on a critical
assumption: that the patient and control groups did not differ in VND. This could not
be directly tested, since VT does not differentiate between VS and VND. If reliable
and valid estimates of [11C]PBR28 specific binding could be obtained, it would allow
for bettered powered and more precise detection of clinical effects.
The SIME method aims to derive estimates of specific binding (such as VS or BPND)
without requiring a reference region. The objective of Study VIII was to evaluate
the accuracy and reliability of SIME applied to [11C]PBR28 data. Specifically, Study
VIII set out to 1) simulate data and examine how accurately SIME could estimate
a known VND value, 2) compare SIME to “gold standard” estimates of VND using
pharmacological challenge data 4) compare SIME derived VND, VS and BPND values
between HAB and MAB subjects and 5) examine the test-retest reliability of SIME
derived outcomes.
First, realistic looking [11C]PBR28 TACs were simulated with a known VND value.
This was done as follows: ROI TACs from KI [11C]PBR28 database (mean age =
45.2 ± 17.0SD; 30 HABs and 24 MABs; 32 males and 22 females) were fitted using
the 2TCM. The residuals of the fits were saved into a library. Residuals from this
library were then sampled and added to a set of noise-free model curves with a known
VND. The sampling was done in such way that the variance-covariance structure
between and within TACs were maintained (see article by Schain et al. (164 ) for
more details). The goal of this procedure is to obtain a more “realistic” looking
set of simulated [11C]PBR28 ROI TACs, compared to only adding Gaussian noise
to model curves. Using noise-free model curves from a HAB and a MAB subjects,
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Figure 3.14: In each plot, 1000 [11C]PBR28 noise instances have been created and
added onto a set of noise-free model curves obtained from a HAB subject (A) or a
MAB subject (B). SIME has then been applied to each instance to estimate VND
(histogram). The “true” underlying VND is shown be the blue vertical line.
the procedure was repeated 1000 times (instances). The results of the simulations
can be thought of as a separate HAB and MAB subject, examined 1000 times with
[11C]PBR28, with a set of ROI TACs for each examination that have a known and
common VND.
SIME was then applied to each simulated instance. The results show that SIME
could estimate the “true” underlying VND value with high accuracy and precision
(Figure 3.14; HAB VND:True = 1.15, mean VND:SIME = 1.17 ± 0.035SD; MAB VND:True
= 0.62, mean VND:SIME = 0.63 ± 0.018SD).
Next, five healthy HAB subjects (mean age = 25.2 ± 7.3SD; all male) underwent a
pharmacological challenge. All subjects performed a baseline [11C]PBR28 followed
by intake of the TSPO receptor agonist XBD173 (10 to 90mg) and a repeat PET
examination. Using the baseline and blocking scans, the Lassen plot (143 ) and
Likelihood Estimation of Occupancy (144 ) methods were used to estimate VND.
SIME was then applied to only the baseline scans. Figure 3.15 show the results from
all three methods. SIME underestimated VND by 19% compared to the Lassen plot,
but showed similar values to the Likelihood Estimation of Occupancy method (-3%).
The differences in SIME derived VND, grey-matter VS and BPND were compared
between HAB and MAB subjects from the KI [11C]PBR28 database. Unexpectedly,
HABs showed higher average VND compared to MABs (Figure 3.16A, Hedges’ g =
0.82). In order to investigate potential reasons for this difference in VND, the AUC,
peaks and shapes of the AIF of HABs and MABs were compared. There were clear
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Figure 3.15: VND estimates from 5 HAB subjects undergoing a XBD173 blocking
challenge, using the Lassen plot, Likelihood Estimation of Occupancy (LEO) and
SIME. SIME was only performed on the baseline scans.
differences in AUC and peak-height between average HAB and MAB AIFs, with
MABs showing higher values (data not shown). This is to be expected since HABs
have much higher binding in the periphery. There was however also a difference
in the shape of the AIF between genotype groups, with HABs showing a steeper
post-peak decay (Figure 3.16B). When using an average AIF for all subjects, the
difference in SIME derived VND observed in Figure 3.16A disappeared (Figure 3.16C,
Hedges’ g = -0.029). Assuming that SIME is valid and unbiased, these results suggest
two possible explanations for the observed genotype difference in VND: 1) There is an
actual biological difference in the non-specific binding or free-fraction of radioligand
between HABs and MABs (due to e.g. difference in active transportation across
the blood-brain barrier); 2) there is a systematic error in the measurement of the
AIF for HABs and/or MABs that affects the estimated VND. To date, there exists
no published [11C]PBR28 blocking data examining VND in MAB subjects. Hence,
the observed difference in VND between genotypes cannot be fully verified, and this
phenomenon warrants further investigation.
VT from the unconstrained 2TCM and SIME derived VS showed large separation in
the whole grey-matter between genotype groups, while to SIME derived BPND values
showed lower separation (Figure 3.16D, E and F). Importantly, the average SIME
VS for HABs (mean = 2.69) was almost exactly double that of MABs (mean = 1.36).
If the SIME method is valid, this is to be expected since the low-affinity allele has
negligible binding of [11C]PBR28 to TSPO, so that HAB subjects will effectively
show twice as many binding sites compared to MAB subjects (89 ).
69
Table 3.5: Means, variability and test-retest metrics for grey-matter VT from the
unconstrained 2TCM and SIME derived outcome measures (VND, VS and BPND).
Measure PET1 Mean (SD) PET2 Mean (SD) ICC AbsVar SEM
2TCM VT 3.41 (1.86) 3.65 (1.84) 0.94 17.54 0.43
SIME VND 1.29 (0.47) 1.35 (0.47) 0.86 18.07 0.18
SIME VS 2.12 (1.55) 2.29 (1.47) 0.93 24.29 0.39
SIME BPND 1.61 (0.76) 1.63 (0.6) 0.65 24.00 0.39
The test-retest reliability and precision of SIME derived outcomes can be seen in
Table 3.5. VS showed excellent reliability, as estimated using the ICC, while BPND
showed lower reliability.
The results from Study VIII suggest that SIME could accurately estimate VND for
[11C]PBR28 examination. VS derived using SIME showed both large separation
between genotype groups, and high reliability. SIME derived BPND values were
however not as reliable and precise. One potential explanation for this is that
small amounts of measurement error in the SIME derived numerator (VS:SIME)
and/or denominator (VND:SIME) used to calculate BPND leads to an amplified and
larger error in the quotient, while this is not the case for subtraction carried out to
calculate only VS (VT:2TCM - VS:SIME). In theory, VS should show higher sensitivity
and power for detecting clinical effects compared to VT. Future clinical [11C]PBR28
studies should therefore use SIME derived VS values in preference, or in addition, to
VT from the unconstrained 2TCM.
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Figure 3.16: Difference between genotype groups in A) SIME derived VND, B) shape
of AIFs, C) SIME derived VND when using an average AIF, D) grey-matter VT from
the unconstrained 2TCM grey-matter, and SIME derived E) VS and F) BPND values.
When an average AIF was used for all subjects, the genotype difference in VND
disappeared (C). Shaded regions in B denotes ±1SE around the average AIFs.
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Chapter 4
Future perspectives
• The negative relationship between Social Desirability and D2-R availability in
striatum is one of the most replicated findings in PET-personality literature.
However, few to no PET-personality studies have been pre-registered, sample
sizes are often very small and it is common that many different regions (even
within the striatum) are examined with insufficient correction for multiple
comparisons. It would therefore be of importance to perform a meta-analysis
of the relationship between Social Desirability scale scores and striatal
D2-R availability. This should preferable be done using both published and
unpublished data. The latter could be obtained by e.g. contacting PET centers
around the world and ask them to share potential unpublished data. In doing
so, a clearer assessment of the robustness of the effect could be obtained and
published.
• The SIME method showed promise in estimating [11C]PBR28 VS. A future
study could hence apply SIME on patient-control data, to yield specific binding
estimates of [11C]PBR28. The hypothesis is that, regardless of the direction
of the results, SIME VS should show higher sensitivity compared to VT. This
would then translate into SIME outperforming the e.g. unconstrained 2TCM
when it comes to quantifying support for, or against, an effect.
• Binding outcome measures are often treated as point-estimated values in PET
literature. I.e. there are few methods or studies that takes the inherent
uncertainty around e.g. VT or BPND into account when performing statistical
inference. Future research could focus on developing and evaluate methods
where the uncertainty in the kinetic modeling is estimated, and accounted for
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in the ensuing statistical inference. A question of interest would be how such an
approach would change the statistical power of analyses and the assessment of
certainty around effects, compared to the way kinetic and statistical modeling
of PET data is carried out today.
• It will likely become more important to advocate for, and perform 1)
pre-registered studies or “registered reports” (165 ), 2) open-data and code
sharing as well as 3) practices leading to reproducible workflows and results,
when doing research in PET. Such objectives would allow for more robust and
trustworthy findings and likely limit questionable research practices, such as
“p-hacking”. In order to ease data sharing and reproducibility, one goal would
be to create publicly available open-source software that can process data all
the way from a standardized “raw” format (e.g. reconstructed dynamic PET
images organized by BIDS structure, (166 )) to outcome measures of interest
(e.g. BPND values) in the same pipeline.
73
Acknowledgments
I would like to thank Simon Cervenka for having been an excellent supervisor and
mentor. The freedom and responsibility you have entrusted me with during these
years are the most important reasons to why I’ve been able to develop skills for doing
science, while also finding it highly rewarding and meaningful. Your loyalty, patience
and leadership have allowed me to always and only focus on science and nothing else.
This is probably the greatest gift a supervisor can give a PhD student.
Granville Matheson – thank you for being my closest friend and companion in almost
all my, more or less successful, scientific endeavors. As the arbiter of my scientific
reasoning and works, my PhD (and everyday life) would have been significantly less
fruitful and fun without you by my side.
Thanks to my co-supervisor Petter Gustavsson for fueling my interest in science,
statistics and music, and to Lars Farde for your wisdom, encouragement and always
saying “yes, go for it” when I asked for data to try out new ideas.
Thank you, Martin Schain, for the scientific and non-scientific guidance you have
provided me with as a co-supervisor and as a friend. Few people have the questionable
honor of being a role (playing?) model to me, but you are one of them.
I would like to thank everybody in room 1300.5: Emma Veldman, Patricimo Fazio,
Max Andersson, Vera Kerstens, Ämma Tangen, and Jonas Svensson for being
awesome friends and co-workers and for stoically withstanding mine and Granville’s
loud fights over many, many trivial scientific matters. You are the reason why I
always enjoyed going to work in the morning, even during the tougher times of
my PhD. Thanks to Miklós Toth, Lenke Tari and Anton Forsberg for all the fun
discussions, for the few but intensive online play sessions, and for enriching my
everyday work experience. Without you all, lunch would not have been near as fun.
Lieke, Nina, William and Björn – thank you for your friendship and for pushing me to
become a better scientist. Spending time with you in the journal club, seminar-series,
74
geek-club or the pub have been among the best parts of my PhD. Remember that
you are always allowed a couple of mulligans (approximately 3-4) in the beginning of
your PhD.
I would like to thank Karin Collste and Pauliina Victorsson for always taking the
time to answer basic and complex questions about psychiatry, sharing your clinical
expertise while also putting my statistics teaching skills to the test.
Zsolt Cselényi, Katarina Varnäs and Andrea Varrone – thank you for the guidance,
experience and technical expertise you have provided me. A big thanks to Urban
Hansson and Göran Rosenqvist for patiently explaining bash code and the physics
of the PET systems (respectively), while always providing technical and logistical
support on very short notice. A big thanks to Karin Zahir and Nina Knave – without
your help I would have stumbled into the pit of administrational issues, and likely
never gotten up. Thanks to Eva Holmgaard for standing watch at the bottom of the
pit, feeding my fear of falling in.
A very big thanks to current and former members of the PET group: Christer
Halldin, Balazs Gulyas, Per Stenkrona, Magdalena Nord, Aurelija Jučaite, Kai-Chun
Yang, Mikael Tiger, Patrik Mattson, Johan Lundberg, Ryosuke Arakawa, Jacqueline
Borg, Sjoerd Finnema, Akihiro Takano, Mahabuba Jahan, Carsten Steiger, Patricia
Miranda-Azpiazu, Pavitra Kannan, Camilla Gustafsson, Rafael Maior, Magnus Schou,
Karin Olsson, Peter Johnström, Vladimir Stepanov, Sangram Nag, Arsalan Amir,
Julio Gabriel, Sara Lundqvist, Zsolt Sarnyai, Matteo Ferrante, Nadja Hellsing,
Marcello Venzi, Malena Kjellén, Jonas Ahlgren, Opokua Britton-Cavaco, Åsa
Södergren, Siv Eriksson, Marie Svedberg and Jenny Häggkvist. A very big thanks to
everybody in the PET group not listed here - without you all my work would not
have been possible.
Thanks to Todd Ogden and Francesca Zanderigo for excellent collaboration,
inspiration and supervision. Thanks to Rita Almeida, Erik Hedman, Ann Rudman,
Predrag Petrovic, Karin Jensen and Bo Melin for scientific support or inspiration
outside the immediate scope of my thesis.
I would like to thank a set of people, most of whom I never met, whose online courses,
online presence, summer schools or participation in podcasts have had an especially
strong impact on the way I think about and do science: Roger Peng, Hillary Parker,
Andrew Conway, Michael Fitzpatrick, Richard McElreath and E.J. Wagenmakers.
75
Thanks to the Gaggia Classic Espresso Machine in the corridor-kitchen for a long and
faithful service. Thanks to Sean “Day[9]” Plott for an amazing one-way friendship
and for providing countless hours of much needed free entertainment during my
PhD. Thanks to the people in the Filosofiska Smådåd-podcast for re-awakening my
slumbering interest in philosophy and enriching my scientific thinking.
Thanks to all my friends: Johan Smedbäck, Mattias Folke and Hanna Eggestrand
for standing by my side all these years and for providing friendship and meaning
outside science; Niels Eék and Daniel Fürth for the never-ending discussions about
the true nature of Elon Musk/apple-products; Vincent Millischer for being a
Kaiserkampfstrudel; and Tomas Folke for the longest friendship of my life, for all the
discussions on politics and philosophy and for making me interested in science as a
teenager.
Finally, I would like to thank my family: Josefin, Edvin, my mom, my dad and my
brothers for everything else that is good in my life. Without you, this thesis would
not have happened.
76
References
1. Azevedo FAC, Carvalho LRB, Grinberg LT, et al. Equal numbers of neuronal and
nonneuronal cells make the human brain an isometrically scaled up primate brain.
Journal of Comparative Neurology. 2009;513:532-541.
2. Kandel ER, Schwartz JH, Jessell TM, Siegelbaum SA, Hudspeth AJ. Principles of
neural science. Vol 4. McGraw-hill New York; 2000.
3. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors.
Neuroscience & Biobehavioral Reviews. 2000;24:125-132.
4. Malenka RC, Nestler EJ, Hyman SE. Chapter 6: Widely Projecting Systems:
Monoamines, Acetylcholine, and Orexin. Sydor A, Brown RY Molecular
Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed) New York:
McGraw-Hill Medical. 2009:147-148.
5. Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and
indirect pathways of basal ganglia: a critical reappraisal. Nature neuroscience.
2014;17:1022-1030.
6. Nieoullon A. Dopamine and the regulation of cognition and attention. Progress in
neurobiology. 2002;67:53-83.
7. Wise RA. Dopamine, learning and motivation. Nature reviews neuroscience.
2004;5:483-494.
8. Volkow ND, Fowler JS, Wang G-J, Swanson JM. Dopamine in drug abuse and
addiction: results from imaging studies and treatment implications. Molecular
psychiatry. 2004;9:557-569.
9. Zhuang X, Mazzoni P, Kang UJ. The role of neuroplasticity in dopaminergic
therapy for Parkinson disease. Nature Reviews Neurology. 2013;9:248-256.
10. Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PRA. The dopamine theory of
77
addiction: 40 years of highs and lows. Nature Reviews Neuroscience. 2015;16:305-312.
11. Grace AA. Dysregulation of the dopamine system in the pathophysiology of
schizophrenia and depression. Nature Reviews Neuroscience. 2016.
12. Herculano-Houzel S. The human brain in numbers: a linearly scaled-up primate
brain. Frontiers in human neuroscience. 2009;3:31.
13. Gehrmann J, Matsumoto Y, Kreutzberg GW. Microglia: intrinsic immuneffector
cell of the brain. Brain Research Reviews. 1995;20:269-287.
14. Raivich G. Like cops on the beat: the active role of resting microglia. Trends in
neurosciences. 2005;28:571-573.
15. Hanisch U-K, Kettenmann H. Microglia: active sensor and versatile effector cells
in the normal and pathologic brain. Nature neuroscience. 2007;10:1387.
16. Garden GA, Möller T. Microglia biology in health and disease. Journal of
Neuroimmune Pharmacology. 2006;1:127-137.
17. Farde L. TSPO binding may also represent ‘resting’microglia. Clinical and
Translational Imaging. 2015;3:491-492.
18. Pelvig DP, Pakkenberg H, Stark AK, Pakkenberg B. Neocortical glial cell numbers
in human brains. Neurobiology of aging. 2008;29:1754-1762.
19. Ransom B, Behar T, Nedergaard M. New roles for astrocytes (stars at last).
Trends in neurosciences. 2003;26:520-522.
20. Graeber MB, Streit WJ. Microglia: biology and pathology. Acta neuropathologica.
2010;119:89-105.
21. Hamby ME, Sofroniew MV. Reactive astrocytes as therapeutic targets for CNS
disorders. Neurotherapeutics. 2010;7:494-506.
22. Halldin C, Stone-Elander S, Farde L, et al. Preparation of 11C-labelled SCH
23390 for the in vivo study of dopamine D-1 receptors using positron emission
tomography. Int J Rad Appl Instrum [A]. 1986;37:1039-1043.
23. Olsson H, Halldin C, Swahn C-GG, Farde L. Quantification of [11C]FLB 457
Binding to Extrastriatal Dopamine Receptors in the Human Brain. Journal of
Cerebral Blood Flow and Metabolism. 1999;19:1164-1173.
24. Chen M-K, Guilarte TR. Translocator protein 18 kDa (TSPO): molecular sensor
78
of brain injury and repair. Pharmacology & therapeutics. 2008;118:1-17.
25. Moses WW. Fundamental limits of spatial resolution in PET. Nuclear Instruments
and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors
and Associated Equipment. 2011;648:S236-S240.
26. Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography
compartmental models. Journal of Cerebral Blood Flow & Metabolism.
2001;21:635-652.
27. Lammertsma AA, Bench CJ, Hume SP, et al. Comparison of methods for analysis
of clinical [11C] raclopride studies. Journal of Cerebral Blood Flow & Metabolism.
1996;16:42-52.
28. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor
studies. Neuroimage. 1996;4:153-158.
29. Salinas CA, Searle GE, Gunn RN. The simplified reference tissue model: model
assumption violations and their impact on binding potential. Journal of Cerebral
Blood Flow & Metabolism. 2015;35:304-311.
30. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor
parameter estimation by linear regression analysis. Journal of Cerebral Blood Flow
& Metabolism. 2002;22:1271-1281.
31. Ichise M, Liow J-S, Lu J-Q, et al. Linearized Reference Tissue Parametric
Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies
of the Serotonin Transporter in Human B rain. Journal of Cerebral Blood Flow &
Metabolism. 2003;23:1096-1112.
32. Logan J. Graphical analysis of PET data applied to reversible and irreversible
tracers. Nuclear medicine and biology. 2000;27:661-670.
33. Ogden RT, Tarpey T. Estimation in regression models with externally estimated
parameters. Biostatistics. 2005;7:115-129.
34. Wiggins JS. A psychological taxonomy of trait-descriptive terms: The
interpersonal domain. Journal of Personality and Social Psychology. 1979;37:395-412.
35. Kiesler DJ. Contemporary interpersonal theory and research: Personality,
psychopathology, and psychotherapy. NY: John Wiley & Sons; 1996.
36. Pincus AL, Wiggins JS. Interpersonal problems and conceptions of personality
79
disorders. Journal of Personality Disorders. 1990;4:342-352.
37. Huang CL, Yang YK, Chu CL, et al. The association between the Lie scale of the
Maudsley personality inventory and striatal dopamine D2/D3 receptor availability
of healthy Chinese community subjects. European Psychiatry: The Journal of the
Association of European Psychiatrists. 2006;21:62-65.
38. Reeves SJ, Mehta MA, Montgomery AJ, et al. Striatal dopamine (D2) receptor
availability predicts socially desirable responding. NeuroImage. 2007;34:1782-1789.
39. Egerton A, Rees E, Bose SK, et al. Truth, lies or self-deception? Striatal D(2/3)
receptor availability predicts individual differences in social conformity. NeuroImage.
2010;53:777-781.
40. Cervenka S, Gustavsson P, Halldin C, Farde L. Association between striatal
and extrastriatal dopamine D2-receptor binding and social desirability. Neuroimage.
2010;50:323-8.
41. Caravaggio F, Fervaha G, Chung JK, et al. Exploring personality traits related
to dopamine D2/3 receptor availability in striatal subregions of humans. European
Neuropsychopharmacology. 2016;26:644-652.
42. Paulhus DL. Two-component models of socially desirable responding. Journal of
personality and social psychology. 1984;46:598.
43. Couppis MH, Kennedy CH, Stanwood GD. Differences in aggressive behavior
and in the mesocorticolimbic DA system between A/J and BALB/cJ mice. Synapse.
2008;62:715-724.
44. Zuckerman M, Michael Kuhlman D, Thornquist M, Kiers H. Five (or three)
robust questionnaire scale factors of personality without culture. Personality and
Individual Differences. 1991;12:929-941.
45. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and
comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey
Replication. Archives of General Psychiatry. 2005;62:617-627.
46. Clark DM, Wells A. A cognitive model of social phobia. Social Phobia: Diagnosis,
Assessment, and Treatment. 1995;41:69-93.
47. Bruce LC, Heimberg RG. Social anxiety disorder. The Wiley Handbook of
80
Cognitive Behavioral Therapy. 2014.
48. Morrow B, Elsworth J, Rasmusson A, Roth R. The role of mesoprefrontal
dopamine neurons in the acquisition and expression of conditioned fear in the rat.
Neuroscience. 1999;92:553-564.
49. McCullough LD, Sokolowski JD, Salamone JD. A neurochemical and behavioral
investigation of the involvement of nucleus accumbens dopamine in instrumental
avoidance. Neuroscience. 1993;52:919-925.
50. Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M.
Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry.
2000;157:457-9.
51. Schneier FR, Abi-Dargham A, Martinez D, et al. Dopamine transporters, D2
receptors, and dopamine release in generalized social anxiety disorder. Depression
and Anxiety. 2009;26:411-418.
52. Freitas-Ferrari MC, Hallak JEC, Trzesniak C, et al. Neuroimaging in
social anxiety disorder: a systematic review of the literature. Progress in
Neuro-Psychopharmacology & Biological Psychiatry. 2010;34:565-580.
53. Brühl AB, Delsignore A, Komossa K, Weidt S. Neuroimaging in social
anxiety disorder—a meta-analytic review resulting in a new neurofunctional model.
Neuroscience & Biobehavioral Reviews. 2014;47:260-280.
54. American-Psychiatric-Association-Task Force on-DSM-IV. Diagnostic and
statistical manual of mental disorders: DSM-IV-TR. American Psychiatric
Publishing, Inc.; 2000.
55. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence
of schizophrenia. PLoS medicine. 2005;2:e141.
56. Ripke S, Neale BM, Corvin A, et al. Biological insights from 108
schizophrenia-associated genetic loci. Nature. 2014;511:421-427.
57. Arias I, Sorlozano A, Villegas E, et al. Infectious agents associated with
schizophrenia: a meta-analysis. Schizophrenia research. 2012;136:128-136.
58. Dalman C, Allebeck P, Gunnell D, et al. Infections in the CNS during childhood
and the risk of subsequent psychotic illness: a cohort study of more than one million
81
Swedish subjects. American Journal of Psychiatry. 2008;165:59-65.
59. Müller N. The role of anti-inflammatory treatment in psychiatric disorders.
Psychiatria Danubina. 2013;25:0-298.
60. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis
of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.
Biological psychiatry. 2011;70:663-671.
61. Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in
medication-naive first episode psychosis: a systematic review and meta-analysis.
Schizophrenia research. 2014;155:101-108.
62. Mizrahi R. Social stress and psychosis risk: common neurochemical substrates?
Neuropsychopharmacology. 2015.
63. Howes OD, McCutcheon R. Inflammation and the neural diathesis-stress
hypothesis of schizophrenia: a reconceptualization. Translational psychiatry.
2017;7:e1024.
64. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in
patients with psychiatric illnesses. Neuroscience letters. 1999;271:126-128.
65. Radewicz K, Garey LJ, Gentleman SM, Reynolds R. Increase in HLA-DR
immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics.
Journal of Neuropathology & Experimental Neurology. 2000;59:137-150.
66. Kellom M, Basselin M, Chen M, Rapoport SI, Rao JS. Increased
Neuroinflammatory and Arachidonic Acid Cascade Markers with Synaptic Marker
Loss in Lipopolysaccharide Infused Rats. The FASEB Journal. 2011;25:615-650.
67. Wierzba-Bobrowicz T, Lewandowska E, Lechowicz W, Stepień T, Pasennik E.
Quantitative analysis of activated microglia, ramified and damage of processes in
the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathologica.
2005;43:81-89.
68. Trepanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP. Postmortem
evidence of cerebral inflammation in schizophrenia: a systematic review. Molecular
psychiatry. 2016;21:1009.
69. Kipnis J. Multifaceted interactions between adaptive immunity and the central
82
nervous system. Science. 2016;353:766-771.
70. Kesteren C van, Gremmels H, Witte LD de, et al. Immune involvement in
the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies.
Translational Psychiatry. 2017;7:e1075.
71. Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor
(Translocator protein 18kDa) in microglia: from pathology to imaging. Progress in
neurobiology. 2006;80:308-322.
72. Toth M, Little P, Arnberg F, et al. Acute neuroinflammation in a clinically
relevant focal cortical ischemic stroke model in rat: longitudinal positron emission
tomography and immunofluorescent tracking. Brain Structure and Function.
2016;221:1279-1290.
73. Notter T, Coughlin JM, Sawa A, Meyer U. Reconceptualization of translocator
protein as a biomarker of neuroinflammation in psychiatry. Molecular psychiatry.
2018;23:36.
74. Edison P, Archer HA, Gerhard A, et al. Microglia, amyloid, and cognition
in Alzheimer’s disease: An [11C](R) PK11195-PET and [11C] PIB-PET study.
Neurobiology of disease. 2008;32:412-419.
75. Debruyne JC, Versijpt J, Van Laere KJ, et al. PET visualization of microglia
in multiple sclerosis patients using [11C] PK11195. European journal of neurology.
2003;10:257-264.
76. Holmes SE, Hinz R, Conen S, et al. Elevated translocator protein in anterior
cingulate in major depression and a role for inflammation in suicidal thinking: a
positron emission tomography study. Biological psychiatry. 2018;83:61-69.
77. Van Berckel BN, Bossong MG, Boellaard R, et al. Microglia activation in
recent-onset schizophrenia: a quantitative (R)-[11 C] PK11195 positron emission
tomography study. Biological psychiatry. 2008;64:820-822.
78. Doorduin J, De Vries EFJ, Willemsen ATM, De Groot JC, Dierckx RA, Klein
HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. Journal
of Nuclear Medicine. 2009;50:1801-1807.
79. Holmes SE, Hinz R, Drake RJ, et al. In vivo imaging of brain microglial activity
in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron
83
emission tomography study. Molecular psychiatry. 2016;21:1672-1679.
80. Van Der Doef TF, De Witte LD, Sutterland AL, et al. In vivo (R)-[11C]PK11195
PET imaging of 18kDa translocator protein in recent onset psychosis. NPJ
schizophrenia. 2016;2:16031.
81. Di Biase MA, Zalesky A, O’keefe G, et al. PET imaging of putative microglial
activation in individuals at ultra-high risk for psychosis, recently diagnosed and
chronically ill with schizophrenia. Translational psychiatry. 2017;7:e1225.
82. Kreisl WC, Fujita M, Fujimura Y, et al. Comparison of [11C]-(R)-PK 11195
and [11C]PBR28, two radioligands for translocator protein (18 kDa) in human and
monkey: Implications for positron emission tomographic imaging of this inflammation
biomarker. Neuroimage. 2010;49:2924-2932.
83. Kobayashi M, Jiang T, Telu S, et al. 11C-DPA-713 has much greater
specific binding to translocator protein 18 kDa (TSPO) in human brain
than 11C-(R)-PK11195. Journal of Cerebral Blood Flow & Metabolism.
2017:0271678X17699223.
84. Wilson AA, Garcia A, Parkes J, et al. Radiosynthesis and initial evaluation
of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nuclear
Medicine and Biology. 2008;35:305-314.
85. Jučaite A, Cselényi Z, Arvidsson A, et al. Kinetic analysis and test-retest
variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human
brain - a PET study in control subjects. EJNMMI research. 2012;2:1.
86. Fujita M, Kobayashi M, Ikawa M, et al. Comparison of four 11C-labeled
PET ligands to quantify translocator protein 18 kDa (TSPO) in human brain:
(R)-PK11195, PBR28, DPA-713, and ER176—based on recent publications that
measured specific-to-non-displaceable ratios. EJNMMI Research. 2017;7:84.
87. Collste K, Forsberg A, Varrone A, et al. Test–retest reproducibility of [11C]PBR28
binding to TSPO in healthy control subjects. European Journal of Nuclear Medicine
and Molecular Imaging. 2016;43:173-183.
88. Owen DRJ, Gunn RN, Rabiner EA, et al. Mixed-affinity binding in humans with
18-kDa translocator protein ligands. Journal of Nuclear Medicine. 2011;52:24-32.
89. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO)
polymorphism explains differences in binding affinity of the PET radioligand PBR28.
84
Journal of Cerebral Blood Flow & Metabolism. 2012;32:1-5.
90. Kreisl WC, Jenko KJ, Hines CS, et al. A genetic polymorphism for translocator
protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain
to this putative biomarker of neuroinflammation. Journal of Cerebral Blood Flow &
Metabolism. 2013;33:53-58.
91. Nair A, Veronese M, Xu X, et al. Test-retest analysis of a non-invasive method
of quantifying [11C]-PBR28 binding in Alzheimer’s disease. EJNMMI research.
2016;6:72.
92. Albrecht DS, Normandin MD, Shcherbinin S, et al. Pseudoreference Regions
for Glial Imaging with 11C-PBR28: Investigation in 2 Clinical Cohorts. Journal of
Nuclear Medicine. 2018;59:107-114.
93. Bloomfield PS, Selvaraj S, Veronese M, et al. Microglial activity in people at
ultra high risk of psychosis and in schizophrenia: an [11C] PBR28 PET brain imaging
study. American Journal of Psychiatry. 2015.
94. Narendran R, Frankle WG. Comment on analyses and conclusions of “microglial
activity in people at ULTRA high risk of psychosis and in schizophrenia: An [11C]
PBR28 pet brain imaging study”. American Journal of Psychiatry. 2016;173:536-537.
95. Turkheimer FE, Edison P, Pavese N, et al. Reference and target region modeling
of [11C]-(R)-PK11195 brain studies. Journal of Nuclear Medicine. 2007;48:158-167.
96. Yaqub M, Van Berckel BN, Schuitemaker A, et al. Optimization of supervised
cluster analysis for extracting reference tissue input curves in (R)-[11C] PK11195
brain PET studies. Journal of Cerebral Blood Flow & Metabolism. 2012;32:1600-1608.
97. Kenk M, Selvanathan T, Rao N, et al. Imaging neuroinflammation in gray
and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA.
Schizophrenia bulletin. 2015;41:85-93.
98. Coughlin JM, Wang Y, Ambinder EB, et al. In vivo markers of inflammatory
response in recent-onset schizophrenia : a combined study using [ 11 C ] DPA-713
PET and analysis of CSF and plasma. Translational Psychiatry. 2016;6.
99. Hafizi S, Tseng HH, Rao N, et al. Imaging microglial activation in untreated
first-episode psychosis: A PET study with [18F]FEPPA. American Journal of
Psychiatry. 2017;174:118-124.
100. Ottoy J, De Picker L, Verhaeghe J, et al. [18F] PBR111 PET Imaging in
85
Healthy Controls and Schizophrenia: Test–Retest Reproducibility and Quantification
of Neuroinflammation. Journal of Nuclear Medicine. 2018:jnumed-117.
101. Fisher RA. The design of experiments. 1935.
102. Fisher RA. The logic of inductive inference. Journal of the Royal Statistical
Society. 1935;98:39-82.
103. Neyman J, Pearson ES. IX. On the problem of the most efficient tests of
statistical hypotheses. Phil Trans R Soc Lond A. 1933;231:289-337.
104. Lee MD, Wagenmakers E-J. Bayesian cognitive modeling: A practical course.
Cambridge university press; 2014.
105. McElreath R. Statistical Rethinking: A Bayesian Course with Examples in R
and Stan. CRC Press; 2018.
106. Fletcher PC, Grafton ST. Repeat after me: replication in clinical neuroimaging
is critical. NeuroImage: Clinical. 2013;2:247.
107. Editorial-staff. Go forth and replicate. Nature. 2016;536:373.
108. Munafò MR, Nosek BA, Bishop DVM, et al. A manifesto for reproducible
science. Nature Human Behaviour. 2017;1:0021.
109. Kerr NL. HARKing: Hypothesizing after the results are known. Personality
and Social Psychology Review. 1998;2:196-217.
110. Schmidt S. Shall we really do it again? The powerful concept of replication is
neglected in the social sciences. Review of General Psychology. 2009;13:90.
111. Begley CG, Ioannidis JPA. Reproducibility in science: improving the standard
for basic and preclinical research. Circulation research. 2015;116:116-126.
112. Poldrack RA, Baker CI, Durnez J, et al. Scanning the horizon: towards
transparent and reproducible neuroimaging research. Nature Reviews Neuroscience.
2017;18:115.
113. Matheson GJ, Stenkrona P, Cselényi Z, et al. Reliability of volumetric and
surface-based normalisation and smoothing techniques for PET analysis of the cortex:
A test-retest analysis using [11C]SCH-23390. NeuroImage. 2017;155:344-353.
114. Hedman E, Andersson G, Ljótsson B, et al. Internet-based cognitive behavior
therapy vs. cognitive behavioral group therapy for social anxiety disorder: a
86
randomized controlled non-inferiority trial. PloS one. 2011;6:e18001.
115. Coughlin JM, Wang Y, Ambinder EB, et al. In vivo markers of inflammatory
response in recent-onset schizophrenia: a combined study using [11C]DPA-713 PET
and analysis of CSF and plasma. Translational Psychiatry. 2016;6.
116. Owen DR, Guo Q, Kalk NJ, et al. Determination of [11C]PBR28 binding
potential in vivo: a first human TSPO blocking study. Journal of Cerebral Blood
Flow & Metabolism. 2014;34:989-994.
117. Gustavsson JP, Bergman H, Edman G, Ekselius L, Knorring L von, Linder J.
Swedish universities Scales of Personality (SSP): construction, internal consistency
and normative data. Acta psychiatrica Scandinavica. 2000;102:217-225.
118. Schalling D, Edman G. Personality and vulnerability to psychopathology: the
development of the Karolinska Scales of Personality (KSP). Stockholm: Karolinska
Institutet. 1987.
119. Nordström P, Schalling D, Asberg M. Temperamental vulnerability in attempted
suicide. Acta Psychiatrica Scandinavica. 1995;92:155-160.
120. Schalling D, Edman G. The Karolinska Scales of Personality (KSP) Manual:
an inventory for assessing temperament dimensions associated with vulnerability for
psychosocial deviance. Stockholm, Sweden: Department of Psychiatry, Karolinska
Institutet. 1993.
121. Ekelund J, Slifstein M, Narendran R, et al. In vivo DA D1 receptor selectivity
of NNC 112 and SCH 23390. Molecular Imaging and Biology. 2007;9:117-125.
122. Halldin C, Farde L, Hogberg T, et al. Carbon-11-FLB 457: a radioligand for
extrastriatal D2 dopamine receptors. J Nucl Med. 1995;36:1275-81.
123. Briard E, Zoghbi SS, Imaizumi M, et al. Synthesis and evaluation in monkey
of two sensitive 11C-labeled aryloxyanilide ligands for imaging brain peripheral
benzodiazepine receptors in vivo. Journal of medicinal chemistry. 2007;51:17-30.
124. Shah F, Hume SP, Pike VW, Ashworth S, McDermott J. Synthesis of the
enantiomers of [N-methyl-11C] PK 11195 and comparison of their behaviours
as radioligands for PK binding sites in rats. Nuclear medicine and biology.
1994;21:573-581.
125. Fujita M, Imaizumi M, Zoghbi SS, Fujimura Y, Farris AG, Suhara T. Kinetic
analysis in healthy humans of a novel positron emission tomography radioligand to
87
image the peripheral benzodiazepine receptor, a potential biomarker for inflammation.
NeuroImage. 2008;40.
126. Boutin H, Chauveau F, Thominiaux C, et al. 11C-DPA-713: a novel peripheral
benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation.
Journal of Nuclear Medicine. 2007;48:573-581.
127. Wienhard K, Dahlbom M, Eriksson L, et al. The ECAT EXACT HR:
performance of a new high resolution positron scanner. Journal of Computer Assisted
Tomography. 1994;18:110-118.
128. Wienhard K, Schmand M, Casey ME, et al. The ECAT HRRT: performance
and first clinical application of the new high resolution research tomograph. IEEE
Transactions on Nuclear Science. 2002;49:104-110.
129. Varrone A, Sjöholm N, Eriksson L, Gulyás B, Halldin C, Farde L. Advancement
in PET quantification using 3D-OP-OSEM point spread function reconstruction
with the HRRT. European Journal of Nuclear Medicine and Molecular Imaging.
2009;36:1639-1650.
130. Bergström M, Boethius J, Eriksson L, Greitz T, Ribbe T, Widen L. Head
fixation device for reproducible position alignment in transmission CT and positron
emission tomography. Journal of Computer Assisted Tomography. 1981;5:136-141.
131. Schain M, Tóth M, Cselényi Z, et al. Quantification of serotonin transporter
availability with [11C]MADAM - a comparison between the ECAT HRRT and HR
systems. Neuroimage. 2012;60:800-807.
132. Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine
transmission with positron emission tomography. Part II: Amphetamine-induced
dopamine release in the functional subdivisions of the striatum. Journal of Cerebral
Blood Flow and Metabolism. 2003;23:285-300.
133. Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. Fsl.
Neuroimage. 2012;62:782-790.
134. Cselényi Z, Olsson H, Farde L, Gulyás B. Wavelet-Aided Parametric Mapping
of Cerebral Dopamine D-2 Receptors Using the High Affinity PET Radioligand [11C]
FLB 457. Neuroimage. 2002;17:47-60.
135. Turkheimer FE, Aston JAD, Banati RB, Riddell C, Cunningham VJ. A linear
wavelet filter for parametric imaging with dynamic PET. Medical Imaging, IEEE
88
Transactions on. 2003;22:289-301.
136. Slifstein M, Laruelle M. Models and methods for derivation of in vivo
neuroreceptor parameters with PET and SPECT reversible radiotracers. Nuclear
Medicine and Biology. 2001;28:595-608.
137. Varnäs K, Varrone A, Farde L. Modeling of PET data in CNS drug discovery and
development. Journal of pharmacokinetics and pharmacodynamics. 2013;40:267-279.
138. Asselin M-C, Montgomery AJ, Grasby PM, Hume SP. Quantification of PET
studies with the very high-affinity dopamine D2/D3 receptor ligand [11C]FLB 457:
re-evaluation of the validity of using a cerebellar reference region. Journal of Cerebral
Blood Flow and Metabolism. 2007;27:378-392.
139. Narendran R, Mason NS, Chen C-M, et al. Evaluation of dopamine D2/3
specific binding in the cerebellum for the positron emission tomography radiotracer
[11C] FLB 457: Implications for measuring cortical dopamine release. Synapse.
2011;65:991-997.
140. Cselényi Z, Olsson H, Halldin C, Gulyás B, Farde L. A comparison of recent
parametric neuroreceptor mapping approaches based on measurements with the
high affinity PET radioligands [11C] FLB 457 and [11C] WAY 100635. Neuroimage.
2006;32:1690-1708.
141. Bloomfield PS, Howes OD, Turkheimer F, Selvaraj S, Veronese M. Response to
Narendran and Frankle: the interpretation of PET microglial imaging in schizophrenia.
American Journal of Psychiatry. 2016;173:537-538.
142. Ogden RT, Zanderigo F, Parsey RV. Estimation of in vivo nonspecific binding
in positron emission tomography studies without requiring a reference region.
Neuroimage. 2015;108:234-242.
143. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring
drug occupancy in the absence of a reference region: the Lassen plot re-visited. J
Cereb Blood Flow Metab. 2010;30.
144. Schain M, Zanderigo F, Ogden RT. Likelihood estimation of drug occupancy
for brain PET studies. NeuroImage. 2018.
145. Verhagen J, Wagenmakers E-J. Bayesian tests to quantify the result of a
replication attempt. Journal of Experimental Psychology: General. 2014;143:1457.
146. Wagenmakers E-J, Verhagen J, Ly A. How to quantify the evidence for the
89
absence of a correlation. Behavior Research Methods. 2016;48:413-426.
147. Collste K, Plavén-Sigray P, Fatouros-Bergman H, et al. Lower levels of the glial
cell marker TSPO in drug-naive first-episode psychosis patients as measured using
PET and [11C]PBR28. Molecular Psychiatry. 2017;22:850-856.
148. Jeffreys H. Theory of probability. 3rd ed. Oxford: Oxford University Press;
1961.
149. Kass RE, Raftery AE. Bayes factors. Journal of the american statistical
association. 1995;90:773-795.
150. Dickey JM. The weighted likelihood ratio, linear hypotheses on normal location
parameters. The Annals of Mathematical Statistics. 1971:204-223.
151. Portney LG, Watkins MP. Foundations of clinical research: application to
practice. 3rd ed.; 2009.
152. Weir JP. Quantifying test-retest reliability using the intraclass correlation
coefficient and the SEM. The Journal of Strength & Conditioning Research.
2005;19:231-240.
153. John LK, Loewenstein G, Prelec D. Measuring the prevalence of questionable
research practices with incentives for truth telling. Psychological science.
2012;23:524-532.
154. Turkheimer FE, Smith CB, Schmidt K. Estimation of the number of “true”
null hypotheses in multivariate analysis of neuroimaging data. Neuroimage.
2001;13:920-930.
155. Chumbley JR, Friston KJ. False discovery rate revisited: FDR and topological
inference using Gaussian random fields. NeuroImage. 2009;44:62-70.
156. Rytwinski NK, Fresco DM, Heimberg RG, et al. Screening for social anxiety
disorder with the self-report version of the Liebowitz Social Anxiety Scale. Depression
and Anxiety. 2009;26:34-38.
157. Stalnaker TA, Cooch NK, Schoenbaum G. What the orbitofrontal cortex does
not do. Nature Neuroscience. 2015;18:620-627.
158. Grupe DW, Nitschke JB. Uncertainty and anticipation in anxiety: an integrated
neurobiological and psychological perspective. Nat Rev Neurosci. 2013;14:488-501.
159. Corlett PR, Fletcher PC. Delusions and prediction error: clarifying the roles of
90
behavioural and brain responses. Cognitive neuropsychiatry. 2015;20:95-105.
160. Matsumoto M, Hikosaka O. Two types of dopamine neuron distinctly convey
positive and negative motivational signals. Nature. 2009;459:837-841.
161. Bromberg-Martin ES, Matsumoto M, Hikosaka O. Dopamine in Motivational
Control: Rewarding, Aversive, and Alerting. Neuron. 2010;68:815-834.
162. Tudur Smith C, Marcucci M, Nolan SJ, et al. Individual participant data
meta-analyses compared with meta-analyses based on aggregate data. The Cochrane
Library. 2016.
163. Cohen J. Statistical power analysis for the behavioral sciences. 1998.
164. Schain M, Zanderigo F, Mann JJ, Ogden RT. Estimation of the binding
potential BPND without a reference region or blood samples for brain PET studies.
NeuroImage. 2017;146:121-131.
165. Chambers CD, Dienes Z, McIntosh RD, Rotshtein P, Willmes K. Registered
reports: realigning incentives in scientific publishing. Cortex. 2015;66:A1-A2.
166. Gorgolewski KJ, Auer T, Calhoun VD, et al. The brain imaging data structure, a
format for organizing and describing outputs of neuroimaging experiments. Scientific
Data. 2016;3:160044.
91
